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Abstract 
 
Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that plays an important role 
in vascular function; with ACE inhibitors being clinically utilised in the treatment of 
cardiovascular disease and diabetic nephropathy. Somatic ACE consists of two homologous 
catalytically active domains (designated N- and C-domains) that share high overall sequence 
identity and structural topology. Despite the high degree of similarity between domains, each 
domain displays differences in substrate processing and inhibitor binding abilities. This 
suggests that active site residues differing between the two domains could provide unique 
interactions within the N-domain that allow for N-selective binding and processing. 
Literature reports of ACE crystal structures and studies with substrate and inhibitor analogues 
have implicated unique residues present in the S2 and S2´ subsites in providing important 
interactions for N-selectivity. 
In order to assess the contribution of residues to N-selectivity, implicated N-domain amino 
acids were converted to their corresponding C-domain counterparts by site-directed 
mutagenesis. Mutant derivatives were expressed in a heterologous mammalian protein 
expression system and purified to h mogeneity by lisinopril-sepharose affinity 
chromatography. Analysis of binding and hydrolysis of non-domain specific substrate 
Abz-FRK(Dnp)P indicated that activities of mutated enzymes were comparable to controls 
with the exception of S2´ mutant ST/VV (which showed a 10-fold decrease in catalytic 
efficiency). S2 mutant Y369F showed improved catalysis of C-domain specific substrate 
hippuryl-His-Leu and reduced catalytic ability of N-selective substrate Abz-SDK(Dnp)P 
implicating the terminal phenolic hydroxyl group in providing important contacts for 
substrate positioning. Other S2 subsite mutations (R381E and YR/FE) also showed decreased 
catalytic efficiency of Abz-SDK(Dnp)P and a C-domain enzyme with an N-domain S2´ 
subsite had 10-fold improved catalysis of this substrate, suggesting interplay between subsites 
in selective substrate processing. A high-throughput AcSDKP assay using fluorescamine was 
also developed and achieved N-domain kinetic characteristics comparable to previous 
reports. 
Binding affinity of RXP407 to mutant active sites served to address the extent of contribution 
of residues to N-selective inhibitor binding. Single S2 and S2´ mutations had little effect on 
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RXP407 binding, as did double S2´ mutant ST/VV. However, double S2 mutant YR/FE 
resulted in a 122-fold increase in Ki, suggesting important contact of both Tyr369 and Arg381 
with RXP407. The importance of the S2 subsite was further emphasised with the addition of a 
P2 Asp and aliphatic N-protecting group improving the N-selectivity of a keto-ACE inhibitor 
backbone, as determined from inhibition assays and molecular docking experiments. This 
work gives an understanding of active site residue contribution to N-selective substrate 
processing and inhibitor binding and has shown consistent involvement of the S2 subsite, 
particularly residues Tyr369 and Arg381, in these events. Further, this study provides 
important information in the design of N-selective ACE inhibitors. 
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Abbreviations and acronyms 
 
°C    degree Celsius 
γ-irradiation   gamma-irradiation 
µl    microlitre 
µM    micromolar 
Å    angstrom 
Aβ    amyloid β-peptide 
Abz    o-aminobezoic acid 
Abz-FRK(Dnp)P  Abz-Phe-Arg-Lys(Dnp)-Pro 
Abz-Gly   o-aminobenzoic acid-glycine 
Abz-SDK(Dnp)P  Abz-Ser-Asp-Lys(Dnp)-Pro 
ACE    Angiotensin-converting enzyme 
ACE2    Angiotensin-converting enzyme 2 
ACEi    Angiotensin-converting enzyme inhibitor 
AcSDKP   N-acetyl-Ser-Asp-Lys-Pro 
ADEs    adverse drug effects 
Ala    alanine 
AngI    angiotensin I 
AngII    angiotensin II 
Ang(1-7)   angiotensin (1-7) 
Arg    arginine 
Asp    aspartic acid 
BK    bradykinin 
BK(1-7)   bradykinin (1-7) 
BK(1-5)   bradykinin (1-5) 
CDOCKER   CHARMm-based docker 
CHARMm   Chemistry at Harvard Molecular Mechanics 
CHO    Chinese hamster ovary  
CPA    carboxypeptidase A 
D629    soluble N-domain construct coding residues 1-629 
dH2O    distilled H2O 
DMSO    dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
Dnp    2,4-dinitrophenyl 
DS    Discovery Studio 
E. coli    Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
ERK    extracellular signal-regulated kinase 
FRET    fluorescence resonance energy transfer 
G418    Geneticin 
Gln    glutamine 
Glu    glutamic acid 
GnRH    gonadotropin-releasing hormaone 
HEMGH   zinc binding motif (His-Glu-Met-Gly-His) 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HHL    hippuryl-His-Leu 
His    histidine 
HL    His(L)-Leu(L) 
HPLC    high pressure liquid chromatography 
IC50    the amount of inhibitor required for 50% residual activity 
kcat    enzymatic turnover rate of substrate 
Ki    inhibition constant 
Km    Michaelis constant 
Lys    lysine 
Met    methionine 
ml    millilitre 
mM    millimolar 
nM    nanomolar 
PAGE    polyacrylamide gel electrophoresis 
PCR    polymerase chain reaction 
PDB    Protein Data Bank (http://www.rcsb.org/pdb)  
Phe    phenylalanine 
pmol    picomole 
POP    prolyl oligopeptidase 
Pro    proline 
RAS    renin-angiotensin system 
RMSD    root mean square deviation 
sACE    somatic angiotensin-converting enzyme 
SD    standard deviation 
SDS    sodium dodecyl sulphate 
SEM    standard error of the mean 
Ser    serine 
Smad    small-mothers-against-decapentaplegic 
tACE    testis angiotensin-converting enzyme 
tACEΔ36NJ modified tACE construct lacking the transmembrane region 
and 36 amino acid N-terminus  
TBE Tris-borate-EDTA buffer 
t-Boc t-butoxycarbonyl group 
TEMED tetramethylethylenediamine 
TGFβ    transforming growth factor β 
Thr    threonine 
Tris    tris-(hydroxymethyl)-aminomethane 
Tyr    tyrosine 
ZBG    zinc binding group 
Z-FHL    Cbz-Phe-His-Leu 
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Chapter 1 
Review of the Literature 
 
1.1 Introduction to angiotensin-converting enzyme related pathologies 
The development and advancement of proteomic techniques has emphasised the vital role of 
proteolytic enzymes in overall cell functioning, with aberrant protease expression and activity 
playing a major role in the progression of numerous disease states (Drag and Salvesen, 2010). 
Thus, appropriate understanding of the structure-function relationships of these enzymes is an 
integral part in the design of therapeutic strategies for many human diseases. Angiotensin-
converting enzyme (ACE, EC 3.4.15.1) is a protease key in the regulation of blood pressure 
and electrolyte homeostasis and has been implicated in a number of disease states particularly 
relating to vascular function (Turner and Hooper, 2002; Acharya et al., 2003). 
The role of ACE in the production of the potent vasopeptide angiotensin II (AngII) is well 
established and the association of ACE and cardiovascular disease is well documented in the 
literature (Lazartigues et al., 2007; Probstfield and O'Brien, 2010). Inhibition of ACE 
remains a frontline treatment in the management of hypertension, a major risk factor in the 
development of cardiovascular disease, and the success of specific ACE inhibitors in the 
treatment of cardiovascular disease stresses the centrality of this enzyme in vascular function 
(Acharya et al., 2003; Bicket, 2002; Ondetti et al., 1977). ACE is pivotal in cardiac 
remodelling (Schartl et al., 1994) and in the pathogenesis of cardiac hypertrophy, with 
overexpression of ACE resulting in increased thickness of cardiomyocytes and collagen 
deposition (Higaki et al., 2000). 
ACE related pathogenesis does occur outside of its classic cardiovascular role. High ACE 
expression has been found in granulomas associated with sarcoidosis (Silverstein et al., 
1979), elevated ACE activity has been correlated in patients with later stages of this disease 
and thus ACE activity is utilised as a diagnostic tool in this condition (DeRemee and 
Rohrbach, 1980; Friedland and Silverstein, 1976; Danilov et al., 2010). Elevated ACE levels 
have also been noted with type 2 diabetes mellitus and higher activities correlated to more 
severely scored retinopathy (Lieberman and Sastre, 1980). ACE is implicated in influencing 
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glucose absorption (Henriksen and Jacob, 2003) and ACE inhibitors have been clinically 
used in reduction of severity of diabetic nephropathy (Burnier and Zanchi, 2006). 
The influence of ACE activity in a variety of states and systems, and the success of ACE 
inhibitors, underpin the importance of this enzyme as a therapeutic target. Thus, appropriate 
studies improving the understanding of the structure-function relationship of ACE are likely 
to allow for better treatment of several disease states. 
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1.2 Angiotensin-converting enzyme 
1.2.1 General properties 
As with proteases thermolysin and neutral endopeptidase; ACE belongs to the gluzincin 
family (MA clan) of metallopeptidases and contains a characteristic HEXXH zinc binding 
motif critical to the metalloenzyme substrate hydrolysis mechanism (Rawlings et al., 2010). 
ACE is a zinc dipeptidyl carboxypeptidase and is best known for its conversion of 
angiotensin I (AngI) to potent vasoconstrictor AngII and the inactivation of vasodilator 
bradykinin (BK); highlighting its important role in blood pressure regulation (Acharya et al., 
2003). The major role in ACE mediated blood pressure regulation is illustrated in 
hypotensive ACE specific knockout mice (Krege et al., 1995; Esther et al., 1996). While this 
is important, it must be stressed that ACE is able to cleave a diverse set of substrates and can 
also exhibit endopeptidase activity in vitro (discussed below) (Skidgel et al., 1984; Skidgel 
and Erdos, 1985; Hu et al., 2001; Sun et al., 2008).   
The Ace gene is located on the 17q23 locus and is 21 kilobases in length consisting of 26 
exons of variable sizes (Figure 1.1) (Hubert et al., 1991). The promoter region consists of a 
classic TATA box upstream of the transcription start site and is regulated by glucocorticoid 
responsive elements (Hubert et al., 1991). In addition, the Ace gene contains an 
insertion/deletion polymorphism of 287 base pair length in intron 16, with the group 
homozygous for the deletion (D/D) generally displaying higher serum ACE activity than the 
insertion (I/I) group (Rigat et al., 1990; Rieder et al., 1999).  
ACE requires the presence of chloride for activity, with several amino acids implicated in 
chloride binding (Shapiro and Riordan, 1983; Tzakos et al., 2003; Rushworth et al., 2008). 
ACE is also heavily glycosylated and this plays an important role in correct intracellular 
folding prior to export, thermal stability (O'Neill et al., 2008; Anthony et al., 2010) and 
possibly dimerisation (Kost et al., 2003). The extent of glycosylation is variable and accounts 
for up to approximately 37% of the total enzyme mass and such glycan heterogeneity 
previously hampered efforts in the determination of ACE crystal structures (Ripka et al., 
1993; Deddish et al., 1994; Yu et al., 1997). The use of expensive glycosidase inhibitors or 
site-directed mutagenesis studies to determine the minimum glycosylation requirements for 
proper folding were employed to circumvent this problem (Natesh et al., 2003; Gordon et al., 
2003; Anthony et al., 2010). 
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Two isoforms, products of the same Ace gene, are detected in tissues as the result of a tissue 
specific promoter within intron 12 (Soubrier et al., 1988; Ehlers et al., 1989; Howard et al., 
1990; Hubert et al., 1991). Somatic ACE (sACE) is expressed as a 1 277 amino acid mature 
protein and is widely expressed in many human tissues, especially on vascular endothelial 
cells (Soubrier et al., 1988). Molecular cloning of the sACE gene revealed the uncommon 
feature of two homologous domains (designated N- and C-domains based on their location on 
the polypeptide chain) each containing a putative active site of which both are catalytically 
active (Soubrier et al., 1988; Wei et al., 1991). In contrast, testis ACE (tACE) is expressed 
exclusively in male germinal cells and is essentially a truncated form of sACE containing 701 
amino acids as a mature protein (Ehlers et al., 1989). With the exception of the first 36 
residues arising from the translation of codons in exon 13; tACE is identical to the C-domain 
region of sACE (Ehlers et al., 1989).  
 
 
Figure 1.1: Schematic representation of the Ace gene and the two isoform products. The Ace 
gene consists of 26 exons all of which are transcribed for sACE with the exception of exon 
13. The promoter for sACE expression is indicated as a grey arrow, sACE N- and C-domains 
with catalytic HEMGH motifs are shown in green and blue respectively, the inter-domain 
linker region in light green, transmembrane region in black and cytoplasmic C-terminus in 
light blue. tACE arises from the presence of a germinal cell specific promoter in intron 12 
(orange arrow) and translation of exon 13 results in a unique 36 amino acid N-terminus of 
tACE; whereas the remainder of the protein is identical to the C-domain of sACE. The black 
arrow indicates the approximate cleavage site of ACE to be solubilised into the surrounding 
medium.   
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The structural elements of the enzyme emphasise its functional role and outline the structural 
similarities between the two isoforms (Figure 1.1). Each isoform contains a 17-amino acid 
hydrophobic sequence that allows for insertion into the plasma membrane as a type I integral 
membrane protein, with catalytic domains in contact with pertinent substrates in the 
extracellular milieu (Soubrier et al., 1988). Despite being anchored in the plasma membrane, 
both isoforms are able to undergo proteolytic cleavage near the transmembrane region by a 
currently unknown protease (termed the ―ACE sheddase‖) and thus released into the 
surrounding environment in soluble form (Ehlers et al., 1996; Woodman et al., 2000).  
1.2.2 The N- and C-domains of ACE  
1.2.2.1 Comparison of the two domains 
Alignment of the N- and C-domains of sACE reveals 60% overall sequence identity and the 
active site regions between the domains are even more conserved with approximately 90% 
similarity (Soubrier et al., 1988). Such high identity between domains is further seen in the 
overall conserved topology of the individual domains (Figure 1.2). 
The overall structure of both the N- and C-domains represents an ellipsoid shape divided into 
two sub-domains by a deep central cleft (Natesh et al., 2003; Corradi et al., 2006). The active 
site containing the catalytic zinc ion of the d mains is buried within this cleft and recent work 
has shown that substrates could possibly gain access into the deep binding site through hinge 
movement by twisting of the N- and C-termini (Anthony et al., 2010). The structures are 
helically rich with only six β-sheets seen in the tertiary structures (Natesh et al., 2003; 
Corradi et al., 2006). Thus far, structural insights have involved studies of each domain in 
isolation, with the crystal structure of the full length sACE currently not determined. Kinetic 
studies have suggested negative cooperativity between the domains in the cleavage of 
substrates (Binevski et al., 2003; Rice et al., 2004; Skirgello et al., 2005). Other work 
implicates the N-domain in close proximity to the C-domain, affecting substrate hydrolysis 
and shedding implying that the domains could be in an intimate orientation to allow for 
interaction between domains (Woodman et al., 2005). The resolution of the sACE crystal 
structure should assist in a structural perspective of this observed cooperativity. 
While the overall topology between domains is very similar, differences in substrate 
processing and inhibitor binding have been noted and could be attributed to the subtle 
changes in amino acid composition within the active sites of the domains (discussed below). 
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Thus, while the domains of sACE are present on the same polypeptide chain, share high 
sequence identity, have almost identical structural topology, and can influence the function of 
each other; each domain appears to have distinctive roles in the overall function of sACE. 
 
 
Figure 1.2: A comparison of the overall topology of the sACE N- and C-domains. The 
coordinates of each domain (PDB accession codes 2C6N and 1O86) were aligned using the 
program ALIGN (Cohen, 1997). The N- (green ribbon) and C-domains (blue ribbon) display 
marked overall structural topology. A potent ACE inhibitor, lisinopril, and the catalytic zinc 
ion are shown in yellow sticks and magenta sphere. A deep central cleft can be noted down 
the centre of the molecules resulting in two sub-domains.  
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1.2.2.2 The role of the C-domain in vivo 
Genetic engineering in mice has allowed for the specific generation of ACE modifications 
including the complete knockout of both ACE isoforms, the generation of tissue specific 
ACE expression and production of domain inactivated sACE forms due to mutation of the 
HEMGH zinc binding motif (Xiao et al., 2004; Bernstein et al., 2010). Such approaches have 
allowed for important in vivo characterisation of ACE related physiology and assist in an 
understanding of the distinctive physiological roles of each domain. 
ACE null mice, in addition to significantly lowered blood pressure, exhibit additional 
anatomical and physiological abnormalities including renal defects, anaemia, lower urinary 
concentration ability and decreased fertility (Krege et al., 1995; Esther et al., 1996). 
Significantly lower fertility was attributed to the removal of the tACE isoform. Additional 
studies indicated that mice lacking tACE had normal anatomy of the testis and showed 
similar sperm viability, in vitro motility and morphology (Hagaman et al., 1998). However, 
sperm of homozygous tACE knockout mice displayed significantly lower transport rates in 
the oviduct and reduced binding to the zonae pellucidae (Hagaman et al., 1998). 
Reintroduction of tACE expression into an ACE null background restored fertility (Ramaraj 
et al., 1998). Rather than a simple structural contribution to sperm binding, fertility is vitally 
dependent on the peptidase activity of ACE acting on a currently unknown substrate (Fuchs 
et al., 2005). 
More recent elegant studies of C-domain function involved the inactivation of each sACE 
domain through the conversion of the HEMGH motif to a non-zinc binding sequence. These 
mice expressed mutant enzymes at comparable levels to wild type mice and allow for an 
understanding of the physiological contribution of each domain (reviewed by (Bernstein et 
al., 2010)). A study involving inactivation of the N-domain showed that these mice were 
indistinguishable from wild type in blood pressure, renal function and hematocrit levels 
(Fuchs et al., 2004). Mice containing the inactivated C-domain enzyme showed increased 
renin and AngI levels and lowered response to AngI infusion; implicating the predominant 
role of the C-domain in the conversion of AngI to AngII (Fuchs et al., 2008). Thus, the 
C-domain plays a primary role in AngI metabolism and male fertility. 
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1.2.2.3 The role of the N-domain in vivo 
Individual soluble and fully active N-domain has been found in the ileal fluid of patients post 
surgical colectomy (Deddish et al., 1994). Since this discovery, active forms of individual 
N-domain enzymes at sizes of 65 kDa and 90 kDa have been found in the urine of healthy 
and hypertensive patients respectively (Casarini et al., 2001). Similar results were found in 
tissue of Wistar-Kyoto and spontaneously hypertensive rats and suggested that the unique 
presence of 90 kDa form of the N-domain in the hypertensive context could be used as a 
marker for hypertension (Marques et al., 2003; Bueno et al., 2004; Ronchi et al., 2005). It is 
possible that the N-domain could be liberated from the sACE molecule by proteolytic action 
and such an event has been shown, in principle, in vitro (Sturrock et al., 1997). These 
findings could suggest an important functioning for the N-domain in physiological regulation.  
In addition to a possible isolated or individual role in tissue, the N-domain plays an 
interesting regulatory role within sACE. Shedding experiments revealed that tACE is shed 
more efficiently than sACE suggesting that the N-domain prevents proper access to the ACE 
sheddase (Woodman et al., 2000). The significance of the physiological ramifications of this 
difference is currently unknown.  
Due to the domain orientation of sACE, the N-domain may be the first domain in contact 
with substrates and inhibitors (Deddish et al., 1996). While the C-domain is prominent in 
AngI conversion in vivo, the N-domain appears to be involved in the cleavage of other 
peptides not necessarily involved in the renin-angiotensin system (RAS, see below). Studies 
with mice have revealed another important role for the N-domain: selective inhibition of the 
N-domain did not affect blood pressure and AngI conversion but resulted in a six fold 
elevation of tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) (Junot et al., 2001). Such 
elevation of AcSDKP plasma levels was later confirmed in N-domain inactivated sACE mice 
and these studies confirmed the selective N-domain function in the clearance of this peptide 
(Fuchs et al., 2004). The involvement and consequences of this peptide are considered below 
(section 1.3.3.2). 
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1.3 Substrates of ACE 
As mentioned above, ACE is able to cleave substrates other than vasoactive peptides. Further, 
each substrate is not hydrolysed with the same efficiency between domains and these 
differences could provide a possible approach in the design of therapeutic strategies of ACE 
related pathologies. 
1.3.1 Mechanism of substrate hydrolysis 
The exact mechanism of ACE substrate hydrolysis remains to be fully elucidated. However, 
since there is high sequence identity and topology between the catalytic centres of ACE and 
thermolysin, it is assumed to proceed in a thermolysin analogous manner and is described in 
detail elsewhere (Matthews, 1988; Sturrock et al., 2004).  
The reaction of thermolysin, and presumably ACE, proceeds through a general-base type 
mechanism. The substrate is positioned and stabilised through interactions within the active 
subsites of ACE, in this case the N-domain. Of importance is the interaction of the C-terminal 
carboxylate with residues Gln259, Lys489 and Tyr498 (Figure 1.3). Optimal interaction of 
the substrate with residues in the active site leads to the displacement of a water molecule 
(previously in coordination with the zinc ion) towards Glu362. The displacement results in an 
enhancement of the nucleophilicity of the water molecule and positions it for nucleophilic 
attack on the substrate carbonyl carbon (Matthews, 1988). The nucleophilic attack leads to 
the formation of the tetrahedral intermediate and the proton taken up by Glu362 is 
immediately transferred to the scissile bond nitrogen atom. This tetrahedral intermediate 
complex has further interactions with Ala332, Tyr501 and His491; where mutation of the His 
residue results in drastic loss of transition state stabilisation (Fernandez et al., 2001), and the 
formation of this tetrahedral substrate intermediate has been noted in the crystal structures of 
ketomethylene inhibitors (Watermeyer et al., 2008). Collapse of the tetrahedral intermediate 
occurs through the transfer of the second water proton by Glu362 to the newly formed 
N-terminal nitrogen atom and the products are released (Figure 1.3) (Sturrock et al., 2004).   
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Figure 1.3: Schematic summary of the mechanism of action in substrate cleavage in the 
N-domain. Cleavage occurs via the nucleophilic attack of the zinc and Glu362 associated 
water molecule. The subsequent tetrahedral intermediate collapses to result in the cleaved 
products. Residues of interest are given and significant contacts shown as broken lines. 
Substrate side chains are designated in the form PN depending on the position to the scissile 
bond (Schechter and Berger, 1967). The R group represents the remainder of the substrate 
peptide chain. Adapted from (Sturrock et al., 2004). 
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1.3.2 Vasoactive peptides: Angiotensin I, bradykinin, angiotensin 1-7 and substance P 
ACE was first isolated and characterised on the basis of its ability to convert AngI 
(DRVYIHPFHL), an inactive decapeptide, to potent vasoconstrictive octapeptide AngII 
(DRVYIHPF) (Skeggs et al., 1954; Skeggs et al., 1956). Since then a better understanding of 
the central role of ACE in the RAS, a system that contributes notably to blood pressure 
regulation and electrolyte homeostasis, has been elucidated. The potent systemic 
vasoconstrictive effects of AngII are mediated through the angiotensin type 1 receptor that 
signals for aldosterone release as well as water and sodium retention (Fyhrquist and 
Saijonmaa, 2008). The downstream effects of AngII receptor mediated activation go beyond 
the more direct effect of vasoconstriction, with AngII being associated with increased 
proliferation, hypertrophy and fibrosis (Turner and Hooper, 2002). With the effects of AngII 
being described, it is not surprising that ACE is associated with disorders of vascular systems 
(section 1.1). 
BK (RPPGFSPFR), a member of the kallikrein-kinin system and product of kallkrein 
cleavage (Kakoki and Smithies, 2009), is currently the best known physiological substrate of 
ACE whereby it has a catalytic efficiency 10-fold higher than the efficiency of AngI 
hydrolysis (Jaspard et al., 1993). In contrast to AngII, BK is a potent vasodilator eliciting its 
effects largely through the BK type 2 receptor resulting in nitric oxide release and 
prostaglandin synthesis (Kakoki and Smithies, 2009). Using its classic dipeptidase activity, 
ACE is able to consecutively produce BK(1-7) and BK(1-5) thus abolishing the vasodilatory 
effects (Jaspard et al., 1993).  
Production of sACE enzymes with only one functional domain allowed for the assessment of 
relative domain contribution to substrate processing. In vitro and in vivo studies have shown 
that BK is cleaved with approximately equal kinetics by both N- and C-domains (Jaspard et 
al., 1993; Georgiadis et al., 2003; Fuchs et al., 2008). While in vitro data indicates that AngI 
is only slightly better cleaved by the C-domain, in vivo mouse work suggests that the 
C-domain active site is physiologically predominant in this process (Wei et al., 1991; Fuchs 
et al., 2008). 
More recently, the discovery of ACE homologue ACE2 provided a new understanding of the 
counter-regulatory actions in AngII production. Angiotensin (1-7) (Ang(1-7), DRVYIHP), a 
product of the carboxypeptidase activity of ACE2 on AngII, is a peptide involved in 
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vasodilation through specific binding and activation of the Mas receptor (Roks et al., 1999; 
Vickers et al., 2002; Santos et al., 2003). Ang(1-7) can function as a weak inhibitor of ACE 
at high concentrations, but is also a substrate of ACE producing angiotensin(1-5) (DRVYI), 
an inactive peptide (Deddish et al., 1998). In vitro analysis indicates that both domains can 
cleave Ang(1-7) with approximately equal kinetics (Rice et al., 2004), although another study 
suggests the cleavage of the peptide is an N-domain specific process (Deddish et al., 1998). 
Substance P (RPKPQQFFGLM-NH2) is a C-terminally amidated undecapeptide tachykinin 
that has vasodilatory properties but also contributes to neurotransmission and pain response 
(Datar et al., 2004). Both in vitro and in vivo studies indicate that ACE is involved in the 
cleavage of substance P through the removal of the C-terminal dipeptide and also through 
unclassical endopeptidase activity (Skidgel et al., 1984; Ehlers and Riordan, 1989; Jaspard et 
al., 1993). Kinetic analysis showed that the C-domain is able to hydrolyse this peptide at a 
modestly faster rate than the N-domain.  
One can appreciate the manner in which ACE activity contributes to vasoaction; whereby 
potent vasoconstrictive peptides are introduced and vasodilatory peptides are removed in a 
given biological system. 
1.3.3 Other substrates not involved in vasoaction 
While the most celebrated role of the ACE domains is in the production of AngII and the 
inactivation of vasodilatory peptides, other peptides are cleaved by ACE that can play key 
roles in human physiology. Th se are presented below. 
1.3.3.1 Gonadotropin-releasing hormone and amyloid β-peptide 
Gonadotropin-releasing hormone (GnRH, pyro-EHWSYGLRPG-NH2, previously referred to 
as leutenising hormone-releasing hormone) is a decapeptide hormone containing protected 
N- and C-termini and is important in fertility and sexual development (Millar et al., 2004). As 
in the case of substance P, cleavage of GnRH occurs through both di- and 
tricarboxypeptidase ACE activity and novel triaminopeptidase activity was noted whereby 
ACE cleaved off the N-terminal tripeptide from the substrate (Skidgel and Erdos, 1985). Both 
domains seem to be involved in C-terminal tripeptide release but N-terminal tripeptidase 
activity is primarily performed by the N-domain (Ehlers and Riordan, 1991; Jaspard et al., 
1993). While this is interesting from a mechanistic perspective, no in vivo studies have shown 
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ACE cleavage of GnRH and thus the ACE-GnRH interaction could lack physiological 
consequence. 
Amyloid β-peptide (Aβ) is an oligopeptide in which polymerisation and aggregation are 
linked to the progression of Alzheimer’s disease (Kehoe, 2009). Work by numerous 
investigators has shown the ability of ACE to cleave Aβ into fragments that lower 
aggregation ability. While there is agreement that ACE cleaves Aβ in vitro, reports differ on 
the cleavage sites; with some authors describing a number of cleavage sites as a result of 
ACE endopeptidase activity while others only a single cleavage site (Hu et al., 2001; 
Hemming and Selkoe, 2005; Oba et al., 2005; Zou et al., 2007; Toropygin et al., 2008; Sun et 
al., 2008). Furthermore there is disagreement in the literature regarding the domain 
specificity of Aβ hydrolysis with some reports showing N-domain specific cleavage (Oba et 
al., 2005; Toropygin et al., 2008) and others maintaining that the processing is not domain 
specific (Hemming and Selkoe, 2005; Sun et al., 2008). These disparate results might be due 
to the different Aβ peptides and ACE forms employed in assays as well as different model 
experimental systems. Meta-analysis associates the ACE D/D polymorphism (and therefore 
increased ACE levels) with reduced risk of developing Alzheimer’s disease (Lehmann et al., 
2005) and mice treated with an ACE inhibitor tended to have increased amyloid deposition in 
the brain (Zou et al., 2007). However, other in vivo research suggested a limited role of ACE 
mediated Aβ cleavage (Hemming et al., 2007). Thus, the exact molecular nature of Aβ 
cleavage by ACE remains controversial (Kehoe, 2009).  
1.3.3.2 N-acetyl- Ser-Asp-Lys-Pro 
French investigators employed a five step purification protocol to identify a tetrapeptide 
capable of potently inhibiting the proliferation of bovine haematopoietic pluripotent stem 
cells (Lenfant et al., 1989). Various standard characterisation techniques lead to the 
identification of the peptide as AcSDKP and the activity of the compound confirmed with a 
synthetically produced molecule resulting in the same biological effects (Lenfant et al., 
1989). The tetrapeptide was found to be produced from the cleavage of thymosin β-4 through 
the action of prolyl oligopeptidase (POP) (Grillon et al., 1990; Cavasin et al., 2004).  
ACE was discovered to be specific in the degradation of AcSDKP in plasma, with 
co-incubation with 1 µM of an ACE inhibitor almost completely preventing AcSDKP 
hydrolysis (Rieger et al., 1993). With the discovery of the two catalytic domains that appear 
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to differ in substrate specificities (Soubrier et al., 1988; Jaspard et al., 1993), further 
investigation probed the domain contribution towards AcSDKP cleavage. This work revealed 
that, despite similar binding affinities between the two domains, the turnover rate of substrate 
hydrolysis was 50-fold higher for the N-domain active site (Rousseau et al., 1995). Unlike 
other substrates that might not have in vivo significance, studies in both mice and humans 
have shown an increase in plasma concentrations of AcSDKP when treated with an ACE 
inhibitor (Azizi et al., 1996; Chisi et al., 2000; Junot et al., 2001). The development of 
N-selective inhibitors could allow for the treatment of conditions whereby AcSDKP buildup 
could be desired without affecting the RAS (Dive et al., 1999; Junot et al., 2001; Azizi et al., 
2001). The details of the physiological effects of AcSDKP are outlined below and suggest the 
usefulness of AcSDKP in disease treatment, especially in conditions relating to excessive 
tissue fibrosis. 
1.3.3.2.1 AcSDKP and haematopoiesis 
The biological effectiveness of AcSDKP was first discovered in light of the peptide’s ability 
to limit the proliferation of blood stem cells (Lenfant et al., 1989) and was found to be 
synthesised in mice, secreted by the bone marrow in long term culture and had wide tissue 
distribution (Wdzieczak-Bakala et al., 1990; Pradelles et al., 1991). These findings 
encouraged investigations into the molecular functioning of this peptide in proliferation 
regulation. AcSDKP is able to inhibit the transition from G1 to S phase of the cell cycle thus 
keeping progenitor cells in the quiescent state (Lombard et al., 1990). It was shown that co-
treatment with AcSDKP incr ased survival in mice administered with a lethal dose of 
cyclophosphamide and thus the investigators could employ higher doses of chemotherapeutic 
agents in decreasing tumour sizes without causing mouse death (Bogden et al., 1991; Masse 
et al., 1998). Other work indicated the ability of AcSDKP to inhibit the proliferation of 
normal progenitor cells but not already committed leukemic cells (Bonnet et al., 1992; 
Cashman et al., 1994).     
Since ACE specifically inactivates AcSDKP in vivo, administration with ACE inhibitors was 
anticipated to show similar proliferation inhibition results to AcSDKP infusion. A study by 
(Chisi et al., 2000) indicated that ACE inhibitor captopril was able both in vitro and in vivo to 
inhibit murine progenitor cells entering the S-phase during chemotherapeutic treatment or 
γ-irradiation. This was correlated with increased plasma concentrations and half-life of 
AcSDKP (Chisi et al., 2000). The implications of these studies prompted expectation of the 
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use of this easily synthesisable peptide or an ACE inhibitor as a co-treatment with 
chemotherapeutic agents to reduce the severity of cancer treatment due to the ability of 
AcSDKP to keep progenitor cells in the quiescent state during therapy (Bogden et al., 1991; 
Chisi et al., 2000). 
A phase I-II clinical study in cancer patients undergoing monochemotherapy sought to 
establish the usability of AcSDKP as a chemotherapy co-treatment agent that would lower 
treatment associated severity. Co-administration of AcSDKP with chemotherapeutic agents 
cytarabine and isofamide showed protection of peripheral blood cells and lowered toxicity 
(Carde et al., 1992). Little development has taken place within the last decade in the literature 
regarding its use in chemotherapy treatment, suggesting that the translation into the human 
setting has not been as effective as anticipated (Comte et al., 1998). This could be due to the 
complexities associated with administration timing and dosage which can differ significantly 
depending on the drug used and could differ in humans compared to mice (Bogden et al., 
1991; Masse et al., 1998). Further, ACE activity has been shown to be elevated upon drug 
administration or irradiation which could result in AcSDKP clearance prior to taking 
biological action (Comte et al., 1998). No clinical trials have been performed with ACE 
inhibitors in the assessment of haemoprotection.  Thus, the use of AcSDKP as a 
chemotherapeutic co-treatment agent currently appears to have limited value. 
1.3.3.2.2 AcSDKP and tissue fibrosis 
Studies over the last decade, particularly by Carretero and co-workers, have resulted in an 
appreciation of another activity of AcSDKP that could have clinical benefit. An initial tissue 
culture model system showed that this peptide was able to inhibit DNA and endothelin-1 
induced collagen synthesis in rat cardiac fibroblasts, confirming that AcSDKP can mediate its 
effects on cell types other than the haematopoietic system (Rhaleb et al., 2001). Such an 
effect was shown in vivo with aldosterone-salt induced hypertensive rats, whereby co-
administration of aldosterone-salt with AcSDKP significantly lowered collagen deposition 
and cell proliferation in the left ventricle and renal cortex without affecting blood pressure 
(Peng et al., 2001). Since then, a similar effect has been noted for a number of tissues 
including interstitial and perivascular tissue of the heart (Peng et al., 2003; Yang et al., 2004; 
Rasoul et al., 2004; Peng et al., 2005; Peng et al., 2007), aortic tissue (Lin et al., 2008) and 
renal tissue (Liao et al., 2010; Wang et al., 2010) in mouse models of hypertension and 
postmyocardial infarction. Inhibition of POP, and therefore inhibition of AcSDKP 
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production, revealed that the regulation and minimisation of collagen deposition is possibly 
the peptide’s major role at endogenous levels (Cavasin et al., 2007). Other mouse models 
have established that the anti-fibrotic effect of AcSDKP is not limited to cardiovascular 
dysfunctions, and has been shown to reduce collagen deposition in diabetic rats (Castoldi et 
al., 2010) and drug-induced lung fibrosis (Li et al., 2010).  
Identification of the predominant anti-fibrotic role mediated by AcSDKP also proposed a new 
mechanism of action for ACE inhibitors, whereby the reduction of fibrosis is not due to the 
reduction of profibrotic AngII levels alone but by the elevation of AcSDKP (Rasoul et al., 
2004). This was further elucidated in an elegant study conducted by (Peng et al., 2005) using 
a monoclonal antibody specific for AcSDKP and able to prevent its physiological action. In 
AngII induced hypertensive rats, treatment with ACE inhibitor or AcSDKP alone was able to 
reduce collagen deposition in cardiac tissue. Inclusion of the monoclonal antibody in co-
treatment with an ACE inhibitor or AcSDKP restored excessive collagen deposition 
comparable to untreated controls, suggesting that the decrease in fibrosis in this model is 
because of AcSDKP buildup due to infusion or ACE inhibition (Figure 1.4). This same effect 
was repeated in aldosterone-salt induced hypertensive rats (Peng et al., 2007). Such work 
emphasised the role of AcSDKP in prevention of excessive collagen deposition in tissue. 
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Figure 1.4: A representative experiment emphasising the anti-fibrotic effects of AcSDKP in 
cardiac tissue (Peng et al., 2005). In a study performed by Peng et al (2005), treatment of 
AngII-induced hypertensive rats with ACE inhibitor captopril (ACEi) or AcSDKP 
significantly reduced collagen deposition in left ventricle interstitial tissue (collagen stained 
red with picosirius red solution). Co-treatment with an anti-AcSDKP monoclonal antibody 
blunted the anti-fibrotic effects of both the ACEi and AcSDKP treatment, implicating the 
anti-fibrotic effects of ACE inhibition with elevation of AcSDKP levels. Image taken from 
(Peng et al., 2005). 
 
The molecular mechanism of the anti-fibrotic effect of AcSDKP is beginning to emerge. As 
in the case of haematopoietic stem cell regulation; AcSDKP is able to slow differentiation of 
bone marrow derived stem cells and thus limited proliferation, migration, activation and 
cytokine release of macrophages, presenting a novel anti-inflammatory mechanism for the 
peptide (Sharma et al., 2008). AcSDKP was also able to prevent maturation of fibroblasts and 
subsequent collagen production when fibroblasts were exposed to transforming growth 
factor β (TGFβ), a fibrosis promoting cytokine (Peng et al., 2010). Detailed research shows 
that AcSDKP blunts the effects of TGFβ signalling through down regulation of the 
TGFβ/small-mothers-against-decapentaplegic (Smad) and extracellular signal-regulated 
kinase (ERK 1/2) pathways (Liu et al., 2009; Peng et al., 2010). AcSDKP induced reduction 
of fibrosis and cardiac remodelling by galectin-3, a lectin that results in the release of TGFβ 
and plays a prominent role in macrophage recruitment and cardiac dysfunction, has also been 
studied and was shown to act through inhibition of the above pathways in mice (Liu et al., 
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2009). The exact mechanism of Smad pathway downregulation is unknown and does not 
involve increasing the intracellular levels of inhibitory Smad 7 (Peng et al., 2010). However, 
AcSDKP has been shown to bind specifically to an uncharacterised receptor in rat cardiac 
fibroblasts and thus could mediate its effects through independent receptor binding (Zhuo et 
al., 2007). Purification and characterisation of this receptor and the signalling pathway this 
activated receptor utilises is the focus of current research. 
Given the findings above, AcSDKP appears to be a promising agent in the treatment of 
fibrotic tissue conditions without affecting blood pressure. In a mouse model system; 
treatment with bleomycin, a potent anti-neoplastic agent that often is discontinued in 
treatment due to increase in lung fibrosis, revealed that N-domain inactivated sACE mice 
displayed significantly lower pulmonary collagen deposition and increased survival with a 
lethal dose of the drug compared to their wild type littermates (Li et al., 2010). These mice 
had increased AcSDKP plasma levels compared to controls and were as susceptible to 
bleomycin induced pulmonary fibrosis when AcSDKP formation was reduced with a POP 
inhibitor, thus implicating AcSDKP in the prevention of drug related fibrosis of the lung (Li 
et al., 2010). N-domain selective (N-selective) ACE inhibition resulted in 5-fold increases in 
plasma AcSDKP levels in mice (Junot et al., 2001), a concentration similar to that obtained in 
the bleomycin study with inactivated sACE N-domain mice (Li et al., 2010). Thus, 
N-selective treatment could result in increased plasma concentrations of AcSDKP that could 
be of therapeutic benefit without affecting blood pressure and could be used in the treatment 
of pulmonary fibrosis, a condition for which there is currently no approved treatments (du 
Bois, 2010). 
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Table 1.1: A summary of selected ACE substrates. Cleavage sites by ACE are indicated by an 
arrow. The broken arrow indicates the sequential cleavage site after removal of the first 
dipeptide. 
Substrate name 
Biological 
action of 
substrate 
Substrate peptide sequence and ACE cleavage 
sites 
Biological 
action of 
product 
Angiotensin I Inactive 
 
D – R – V – Y – I – H – P – F – H – L 
 
Vasoconstriction 
Hypertrophy 
Fibrosis 
Bradykinin Vasodilation 
 
R – P – P – G – F – S – P – F – R 
 
Inactive 
Angiotensin (1-7) Vasodilation 
 
D – R – V – Y – I – H – P Inactive 
Substance P 
Vasodilation 
Pain response 
 
R – P – K – P – Q – Q – F – F – G – L – M -NH2  
 
Inactive 
Gondotropin-
releasing hormone 
Sexual       
development 
 
pyro-E – H – W – S – Y – G – L – R – P – G -NH2 
 
No in vivo data 
published 
N-acetyl-SDKP Anti-fibrosis 
 
Ac-S – D – K – P 
 
Inactive 
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1.4 Inhibitors of ACE 
1.4.1 First generation ACE inhibitors 
Currently approved ACE inhibitors are successfully used in the treatment of hypertension, 
congestive heart failure, post myocardial infarction, left ventricular dysfunction and diabetic 
nephropathy (Bicket, 2002). Several insights were important to the development of the first 
ACE inhibitors. Ondetti and co-workers used the crystal structure and functional 
understanding of carboxypeptidase A (CPA) as a mechanistic model that could be treated as 
analogous to ACE (although, when the structures of ACE were resolved, this was not found 
to be the case) (Ondetti et al., 1977; Natesh et al., 2003). With the discovery and structural 
determination of the various BK potentiating peptides from snake venom of Bothrops 
jararaca (with the most potent peptides having a Phe-Ala-Pro sequence on the C-terminus) 
and the development of the benzylsuccinic-Pro inhibitor for CPA, Ondetti and Cushman 
synthesised an analogue in the form of methylsuccinyl-Pro that was found to have specific 
but relatively weak ACE inhibition (Cushman et al., 1973; Byers and Wolfenden, 1973; 
Ondetti et al., 1977). The conversion of the zinc binding group (ZBG) from a carboxylate to 
sulphydryl resulted in potent ACE inhibitor captopril that was approved for clinical use in 
1981 (Figure 1.5) (Ondetti et al., 1977; Cushman et al., 1981). 
Adverse effects of captopril treatment, including skin rash and loss of taste, resulted in the 
development of other inhibitors of the Phe-Ala-Pro tripeptide sequence containing a ZBG 
other than a sulphydryl moiety. This initiated a search for N-carboxymethyl dipeptides with 
comparable inhibition to captopril. The dipeptides showing the greatest ACE inhibition were 
Ala-Pro and Lys-Pro and the result was the production of enalaprilat and lisinopril, a new 
class of ACE inhibitors (Figure 1.5) (Patchett et al., 1980). Since the finding that ACE 
inhibition significantly contributes to reduction of blood pressure, 17 ACE inhibitors 
containing different ZBGs and functionalities have been synthesised and approved for 
marketing (Redelinghuys et al., 2005). 
Currently approved ACE inhibitors display binding affinity in the low nanomolar range and 
bind without any major selectivity between the N- and C-domains (Wei et al., 1991). While 
the major effect of first generation ACE inhibitors is the blockade of AngII production and 
the elevation of vasodilator BK; other studies indicate a possible cross talk between ACE and 
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the BK type 2 receptor, agonising the effects of BK as a result of ACE inhibitor binding 
(Erdos et al., 2010) 
. 
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Figure 1.5: Chemical structures of a selecti n of ACE inhibitors. Captopril, enalaprilat and 
lisinopril are clinically approved ACE inhibitors for the treatment of hypertension, heart 
failure and diabetic nephropathy. RXP407 and RXPA380 are phosphinic peptidomimetic 
inhibitors that are selective for the N- and C-domains respectively. 
 
1.4.2 A structural perspective of ACE inhibitor binding 
Side chains of inhibitors and substrates have traditionally been given in the form 
PN...P2, P1, P1´, P2´...PN´ based on their insertion and interaction with the corresponding 
SN...S2, S1, S1´, S2´...SN´ subsites (flanking the scissile bond) within the enzyme (Schechter 
and Berger, 1967). The determination of the crystal structures has allowed for an 
understanding of inhibitor binding at the atomic level and for the visualisation of the 
obligatory inhibitor binding sites within the ACE active sites. The resolution of the N-domain 
and tACE (C-domain, all residues described in tACE numbering) in complex with lisinopril 
reveals a very similar overall binding mode of the inhibitor in both active sites (Figure 1.6). 
The inhibitor carboxylalkyl carboxylate in both cases is coordinating the zinc ion and the P1 
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phenylalanine extends into the corresponding S1 subsite to interact with Thr496/Val518 of the 
N- and C-domains respectively (Natesh et al., 2003; Corradi et al., 2006). The P1´ lysyl 
moiety has interactions with unique C-domain S1´ residues Glu162 and Asp377 (replaced by 
Asp140 and Gln355 in the N-domain respectively) which explains the very slight increase in 
potency for the C-domain compared to the N-domain and why lisinopril is a slightly more 
potent inhibitor than enalaprilat which only possesses a methyl in the P1´ position (Natesh et 
al., 2004). The P2´ prolyl carboxylate moiety has significant interactions with conserved 
residues Gln259/281, Lys489/511 and Tyr498/520 (N/C numbering) and these residues have 
been suggested to be key in substrate and inhibitor positioning (Natesh et al., 2004; Corradi 
et al., 2006; Sturrock et al., 2004). 
 
 
Figure 1.6: Lisinopril binding orientation in the N- (green) and C-domain (blue) active sites. 
Important contact residues and their corresponding domain counterparts for lisinopril are 
shown as well as the nomenclature of inhibitor functional group positioning in black 
(Schechter and Berger, 1967). Lisinopril and the catalytic zinc ion are shown in yellow and 
magenta respectively. Image generated using PyMOL software (v 0.99, DeLano Scientific). 
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1.4.3 The need for second generation, N-selective ACE inhibitors 
ACE inhibitor treatment is effective in lowering blood pressure. While efficacy is noted in 
many cases, adverse drug effects (ADEs) have been associated with ACE inhibitor treatment 
that can lead to discontinuation of drug administration and can be life threatening (Speirs et 
al., 1998; Morimoto et al., 2004). The issues pertaining to the molecular basis of ACE 
inhibitor associated ADEs are complex but the elevation of BK due to ACE inhibition has 
been implicated as a key contributor to these events (Nussberger et al., 1998; Emanueli et al., 
1998; Adam et al., 2002).  
First generation ACE inhibitors bind in the low nanomolar range to both domains of sACE 
(Wei et al., 1992). Since BK is cleaved with approximately equal efficiency between 
domains, and the C-domain active site is the predominant site of AngI conversion in vivo, 
development of low molecular weight inhibitors that selectively inhibit the C-domain 
(C-selective) have been hypothesised to lower AngII production while leaving the N-domain 
free to degrade BK (Acharya et al., 2003; Ehlers, 2006). Such molecules could have 
efficacious effects in lowering blood pressure with possibly reduced incidences of ADEs due 
to lower BK levels. 
The domain selective inhibition hypothesis can also be extended to the development of novel 
N-selective inhibitors. This is due to the compelling in vivo evidence describing the buildup 
of AcSDKP due to general ACE (non-domain selective) inhibition, N-selective inhibition and 
N-domain inactivation (Azizi et al., 1996; Junot et al., 2001; Fuchs et al., 2004) and the 
subsequent beneficial effects of elevated AcSDKP in minimising fibrosis in cardiac, renal 
and pulmonary tissue (Peng et al., 2003; Liao et al., 2010; Li et al., 2010). The development 
of orally available, clinically relevant inhibitors could be useful in the treatment of fibrotic 
conditions without affecting blood pressure; with possible use in the treatment of idiopathic 
and drug-induced pulmonary fibrosis with reduced side effects common to ACE inhibitor 
administration.  
1.4.4 RXP407: an N-selective ACE inhibitor 
1.4.4.1 Structural features of RXP407 
RXP407 (Ac-Asp-(L)Pheψ(PO2-CH2)(L)Ala-Ala-NH2) is a phosphinic-based peptidomimetic 
inhibitor that displays three orders of magnitude N-selectivity and can be used as an initial 
template for the design of novel N-selective compounds (Dive et al., 1999). RXP407 utilises 
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a phosphinate moiety (R-PO2-CH2-R´), a functional group analogous to the transition state of 
a substrate carbonyl, as the ZBG for this inhibitor (Figure 1.5). This is important since the 
zinc binding ability of phosphinates is lower than hydroxymate and thiolate containing 
compounds, thus the overall potency is determined by interactions with amino acids within 
the ACE active sites and not by almost exclusively zinc binding alone (Dive et al., 2004).  
The discovery of RXP407 involved a combinatorial chemistry approach and the screening of 
a large phosphinic library. Maintaining a Ac-P2-Pheψ-(PO2-CH2)-Ala-P2´-NH2 backbone, all 
naturally occurring amino acids were tested in the P2 position for inhibition of the N- and 
C-domains; with Asp showing the greatest N-selectivity. Assessment of the P2´ residue best 
suited for N-selectivity revealed no residues that significantly contributed to selectivity, with 
an Ala residue in that position having the greatest effect out of a selection of poorly 
N-selective molecules. This approach allowed for the generation of an inhibitor that 
possessed unusual structural characteristics compared to other previous ACE inhibitors; 
namely a C-terminal amide (as opposed to the classic carboxylate) and the extension of an 
acetylated N-terminal Asp residue into the P2 position (Figure 1.5) (Dive et al., 1999). 
The synthesis of RXP407 analogues containing changes of significant inhibitor functional 
groups revealed important structural determinants for N-selective binding, with a free N- or 
C-terminus and the replacement of the Asp residue with Ala causing a substantial decrease in 
N-selectivity (Dive et al., 1999). The relative extent of contribution of these groups can be 
summarised as C-terminal amide > P2 Asp > N-acetyl (Dive et al., 1999). These findings not 
only implicate the importance of these functional groups in N-selectivity, but also implicate 
the N-domain S2 and S2´ subsites in providing significant interactions for N-selective binding. 
1.4.4.2 The RXP407–N-domain structure 
Prior to the determination of the RXP407–N-domain co-crystal structure, investigators made 
use of the other available structures to gain insight as to the binding mode of RXP407 in 
N-selective binding. Tzakos and Gerothanassis (2005) performed homology modelling of the 
newly solved tACE structure to generate a three dimensional structure of the N-domain and 
modelled RXP407 on the basis of the positioning of a phosphinic inhibitor analogue in the 
crystal structure of astacin, another zinc peptidase (Tzakos and Gerothanassis, 2005). These 
authors found that the N-acetyl group of RXP407 was in position to interact with unique 
residues Tyr369 and Arg381. These interactions are lost in the C-domain with these residues 
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being replaced by Phe391 and Glu403, respectively (tACE numbering). The P2 Asp, also 
important for selective binding, had a salt bridge interaction with conserved residue Arg500 
while the C-terminal amide made contact with Glu431 in the N-domain. Glu431 is replaced 
by Asp354, an acidic residue that has a shorter side chain length (Tzakos and Gerothanassis, 
2005). Corradi et al. (2006) utilised the newly solved N-domain crystal structure (PDB 
accession code 2C6N) to perform approximate inhibitor positioning using molecular docking 
techniques and found an inhibitor binding orientation similar to that presented above (Corradi 
et al., 2006). Jullien et al. (2006) also performed homology modelling of the C-domain 
followed by energy minimisations of the RXP407 ligand in the active site and showed the C-
terminal amide in contact with Glu431 and within 5 Å of residues Ser357 and Thr358 (Jullien 
et al., 2006). These hydrophilic residues are replaced by bulkier, hydrophobic residues 
Val379 and Val380 and optimisation of interaction with these valines are considered 
important for the C-selectivity of RXPA380 (Corradi et al., 2007). All models agree with 
each other regarding the approximate positioning of the inhibitor P2´ amide, however, the 
model proposed by Jullien et al. suggests that the P2 Asp interacts with residues Tyr369 and 
Arg381 as opposed to the N-acetyl group of the inhibitor (Jullien et al., 2006). Recently, 
overlay of the RXP407–AnCE (an ACE homologue in Drosophila melanogaster) crystal 
structure with the N-domain resulted in investigators making a similar observation (Akif et 
al., 2010a). This presents a possible structural basis for the greater contribution of the P2 Asp 
to N-selectivity whereby the inhibitor residue interacts with unique residues in the N-domain 
as opposed to a conserved Arg residue. 
The recently solved RXP407–N-domain co-crystal structure sheds light on the 
appropriateness of the models proposed previously and is in more agreement with the model 
reported by Jullien et al. (2006) and Akif et al. (2010a), whereby Tyr369 and Arg381 contact 
the P2 Asp of RXP407 (PDB accession code 3NXQ) (Anthony et al., 2010). In the crystal 
structure, the inhibitor has 12 direct hydrogen bonds with residues in the S2, S1´ and S2´ 
subsites (Figure 1.7). In the S2 subsite, the P2 Asp is noted to have up to four hydrogen bonds 
with residues Tyr369 and Arg381. Of all the direct hydrogen bonds detected, Tyr369 and 
Arg381 are the only residues that differ to their corresponding C-domain counterparts. 
Interestingly, the two molecules of the asymmetric unit of the crystal cell show two different 
positions of the N-acetyl group of RXP407, with this functional group not making direct 
contact with the protein. The C-terminal amide (in the P2´ position) of the inhibitor makes 
direct contact with Tyr498, His491 and Gln259 in the S2´ subsite. These three residues are 
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conserved between domains and have traditionally been considered important for inhibitor 
binding (Natesh et al., 2003). In addition, a water mediated hydrogen bond is possible 
between the amide oxygen of the inhibitor and Thr358, and this interaction could be lost in 
the C-domain due to the replacement with Val380 (Anthony et al., 2010). The exact and 
significant contribution of the S2´ subsite to N-selectivity is thus not very clear from the 
crystal structure but suggested from the RXP407 analogues (Dive et al., 1999). The crystal 
structure provides strong evidence for the contribution of the S2 subsite to N-selective 
binding of RXP407. 
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Figure 1.7: The RXP407–N-domain co-crystal structure (PDB accession code 3NXQ). 
Residues of interest for the N- and C-domains are shown as green and blue sticks respectively 
in the S2 (A) and S2´ (B) subsites. The catalytic zinc ion is shown in magenta, RXP407 in 
yellow and residues conserved between domains in black. A water molecule that could 
possibly be involved in an interaction between the C-terminal amide and Thr358 is given as a 
small blue sphere. The RXP407–N-domain crystal structure was structurally aligned to the 
RXPA380–tACE co-crystal structure (PDB accession code 2OC2) using the program ALIGN 
(Cohen, 1997). tACE numbering used for all C-domain residues. Image generated using 
PyMOL software (v 0.99, DeLano Scientific). 
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1.5 Molecular basis for N-selectivity of substrates and inhibitors 
 1.5.1 The S2´ subsite 
The removal of the P2´ C-terminal amide from RXP407 and the subsequent drastic loss of 
N-selectivity implicates residues in the S2´ subsite providing interactions for N-selective 
binding (Dive et al., 1999). While it is not clear from the crystal structure as to the exact 
nature of this involvement, the S2´ subsite contains several residues that differ to their 
corresponding C-domain amino acids (Corradi et al., 2006).  
Residues Ser357 and Thr358 are found on the border of the S2´ subsite and, when compared 
to the C-domain S2´ subsite, result in a spatially smaller and more hydrophilic environment 
(Figure 1.7). The change in subsite size and hydrophobicity in selectivity is emphasised with 
inhibitors containing P2´ Trp residues, as in the case of RXPA380, being orders of magnitude 
more C-selective (Georgiadis et al., 2004; Corradi et al., 2007). 
There are a host of acidic residues present in the S2´ subsite that differ from their C-domain 
counterparts in length or polar nature. Glu262, Asp354, Glu431 residues are replaced by Ser, 
Glu and Asp residues respectively in the C-domain and such changes in acidic nature within 
this subsite could possibly contribute to preferred binding of RXP407 in the N-domain active 
site (Figure 1.7 and 1.8) (Corradi et al., 2006). 
1.5.2 The S2 subsite 
The removal of the RXP407 N-acetyl group and P2 Asp residue result in molecules with 
markedly reduced N-selectivity (Dive et al., 1999). The co-crystal structure of RXP407 in the 
N-domain active site shows the ability of the P2 Asp to make significant contacts with unique 
N-domain residues Tyr369 and Arg381 (Anthony et al., 2010). Further work on a keto-ACE 
inhibitor template indicated the presence of a phenyl group in the P2 position allowed for 
improved C-domain inhibition, with molecules containing aliphatic moieties being less 
C-selective (Nchinda et al., 2006b). This change in selectivity was attributed to repulsion of 
the P2 phenyl by Tyr369 thus not allowing for stronger binding affinity in the N-domain, 
whereas the corresponding Phe391 in the C-domain can better accommodate such a group. 
An aliphatic group could presumably fit into the slightly smaller N-domain S2 subsite 
(Nchinda et al., 2006b). 
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In addition to inhibitor functionalities, previous reports studying the synthetic modifications 
of substrates have implicated the S2 subsite in contributing to N-selective substrate 
processing. Michaud et al. (1997) reported that AcSDKP analogue hippuryl-Lys-Pro was 
cleaved with equal efficiency between domains and thus the determinants for N-selective 
processing lay beyond the C-terminal dipeptide (Michaud et al., 1997). Extension analogues 
were synthesised and extension into the P1 and P2 positions was able to partially restore 
N-selective processing (Michaud et al., 1999). Production of an internally quenched 
fluorogenic equivalent of AcSDKP, Abz-SDK(Dnp)P, confirmed the involvement of the S2 
subsite in substrate selectivity (Araujo et al., 2000). Modification of the P2 Ser to a Thr 
residue had little effect on selective substrate processing, and conversion to more 
hydrophobic Tyr and Phe residues resulted in sequential decreases of N-selective processing, 
suggesting that the presence of an aliphatic alcohol in the P2 position was a major contributor 
to N-selective substrate processing (Araujo et al., 2000). Thus, although general ACE 
substrate specificity can be determined by the prospective substrate C-terminal tripeptide 
(Bunning et al., 1983), a large requirement for N-domain specific cleavage appears to lie 
beyond the S1 subsite (Michaud et al., 1999). 
The presence of Tyr369 and Arg381 as unique N-domain residues that appear to have 
potentially substantial contributions to the selective binding of inhibitor RXP407 has been 
emphasised above. Another residue, Thr496, is present on the border of the S2 and S1 subsites 
and is replaced in the C-domain by hydrophobic Val518 (Figure 1.7 and 1.8) (Corradi et al., 
2006). This allows for an extra potential hydrogen bond which could provide an important 
contact for the binding and positioning of substrates and novel inhibitors. 
Thus previous literature reports implicate both the S2 and S2´ subsites, and residues located 
within these subsites, in N-selective binding and processing. Unique residues are present in 
other subsites; Asp140 and Gln355 of the S1´ subsite have been presented above whereby 
their replacement (with Glu162 and Asp377 in the C-domain) could account for a slight 
increase in the potency of lisinopril for the C-domain compared to enalaprilat (Figure 1.6). 
Two residues in the S1 subsite, namely Ser119 and Asn494, are replaced by Glu143 and 
Ser516 in the C-domain (Corradi et al., 2006). However, these residues have not been 
implicated in N-selectivity for two main reasons. Firstly, structural modification of inhibitors 
and substrates suggest the S2 and S2´ subsites contribute to N-selective binding (as discussed 
above). Secondly, the available crystal structure indicates that the residues in the S1 and S1´ 
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subsites are distant from RXP407 (Anthony et al., 2010). Therefore, an analysis of residue 
contribution to N-domain selective binding and processing by mutagenesis, a study not 
performed before, should commence with a thorough investigation of the S2 and S2´ subsites. 
 
 
Figure 1.8: Schechter and Burger representation of subsites and residues implicated in 
N-selectivity. N-domain residues and their corresponding C-domain counterparts are shown 
in green and blue respectively (tACE numbering for C-domain residues). Catalytic zinc ion 
represented as a magenta sphere and a representative backbone of an inhibitor with 
corresponding functional groups that insert into the respective subsites is shown in dark 
yellow. Thr496/Val518 is represented between the S1 and S2 subsites due to this residue 
being classed as a residue that borders the two subsites. 
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1.6 Hypothesis statement 
The presence of unique N-domain active site residues (that is, with different corresponding 
C-domain counterpart residues) provide distinct and important interactions with substrates 
and inhibitors to allow for N-selective binding and processing. 
1.7 Aims and objectives 
The two domains of sACE display high sequence identity and structural topology but differ in 
inhibitor binding and substrate processing abilities, suggesting that subtle changes in amino 
acid composition between the domains confer differences in domain selectivity. The aim of 
this work is to further elucidate the structure-function relationship of ACE N-selectivity by 
kinetically assessing residue contribution towards substrate processing and inhibitor binding. 
The objectives of the current studies are as follows: 
1. To generate mutations of N-domain residues implicated in N-selectivity (outlined in 
section 1.5) by the conversion into the corresponding C-domain counterparts via site-
directed mutagenesis and heterologous protein expression. 
2. To kinetically assess the effect of these mutations on the processing of domain 
selective substrates. 
3. To further test the effect of these mutations on the binding of RXP407 and to use this 
information in the design of novel N-selective inhibitor analogues. 
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Chapter 2 
Mutagenesis, cloning, expression and purification of N-domain enzymes 
 
2.1 Introduction 
Whilst sACE contains two domains that are similar in both sequence identity and structural 
topology, each domain possesses different inhibitor binding and substrate catalysis abilities. 
This suggests that the unique amino acid residues present in each of the domain active sites 
could provide distinctive interactions and thus contribute to the observed domain selectivity 
of the ACE molecule. Identification of residues important for such selectivity would not only 
aid in understanding of ACE domain substrate specificity but, perhaps more importantly, aid 
in the structure based design of domain selective ACE inhibitors. Specifically, N-selective 
ACE inhibitors could be useful in the clinical setting for the potential treatment of pulmonary 
fibrosis (reviewed in Chapter 1). 
Mutagenic conversion of amino acids is a standard approach used to identify key amino acids 
in enzyme function and has been used to successfully elucidate the structure-function 
relationships of both the C-domain of ACE and homologue ACE2 (Rushworth et al., 2008; 
Watermeyer et al., 2008). Such an approach involves the conversion of key amino acids to 
their corresponding domain counterparts by codon modification using site-directed 
mutagenesis; an approach utilising a modified polymerase chain reaction (PCR) and 
complementary primers to introduce the mutation followed by mutation identification with 
restriction endonuclease selection (Papworth et al., 1996; McPherson, 1990). Residues in 
both the S2 and S2´ subsites of the N-domain active site have been implicated in the 
contribution toward substrate and inhibitor specificity (reviewed in Chapter 1). Thus, these 
residues have been converted to their corresponding C-domain counterparts (Table 2.1). 
Enzymes are expressed in mammalian cell tissue culture to fulfil the glycosylation 
requirements for ACE folding and activity and purified using a simple affinity 
chromatographic procedure for further kinetic analysis (Bull et al., 1985). 
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Table 2.1: Summary of proposed mutants produced and subsequent naming nomenclature. 
Subsite Mutant name 
N-domain residue 
converted 
Introduced C-domain 
residue (tACE numbering) 
S2 
Y369F Tyr369 Phe391 
R381E Arg381 Glu403 
YR/FE Tyr369, Arg381 Phe391, Glu403 
T496V Thr496 Val518 
S2´ 
E262S Glu262 Ser284 
D354E Asp354 Glu376 
S357V Ser357 Val379 
T358V Thr358 Val380 
ST/VV Ser357, Thr358 Val379, Val380 
E431D Glu431 Asp453 
 
The objectives for the production of N-domain enzymes with mutations in the S2 or S2´ 
subsites were as follows: 
1. Conversion of N-domain (D629) codons to corresponding C-domain counterparts 
using a site-directed DpnI approach and confirmation of mutation incorporation by 
nucleotide sequencing. 
2. Cloning of D629 coding regions containing mutations of interest into mammalian 
expression vector pcDNA 3.1 (+). 
3. Transfection and bulk expression of N-domain enzymes in a mammalian cell culture 
system. 
4. Enzyme purification by lisinopril-sepharose affinity chromatography. 
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2.2 Methods 
2.2.1 Enzymes employed and preparation of pBS-D629 
A modified tACE construct, tACEΔ36NJ, that lacks the transmembrane region and unique 36 
amino acid N-terminus (and therefore identical to the sACE C-domain; hereon referred to as 
C-domain) had been generated and transfected previously (Ehlers et al., 1996). A soluble 
form of the N-domain, consisting of amino acids 1 to 629 of somatic ACE (hereon referred to 
as D629 to refer to the DNA coding region or N-domain to refer to protein), in vector pECE 
was a kind gift from Dr S. Danilov and was cloned into sequencing vector pBlueScript SK+ 
(pBS, Invitrogen) as previously described (Balyasnikova et al., 2003; Corradi et al., 2006). 
This plasmid was transformed into competent DH5α E. coli bacteria and plated onto 
ampicillin (50 µg/ml) agar plates (Appendix A1). A single ampicillin resistant clone was 
selected, grown overnight in ampicillin containing medium (luria broth containing 50 µg/ml 
ampicillin) and plasmid DNA extracted and purified using the Qiagen Mini-prep kit (Qiagen 
Corp). Purity, integrity and identity of the pBS-D629 construct was assessed through EcoRI 
and XbaI (Fermentas Life Sciences) restriction digests followed by agarose gel 
electrophoresis with ethidium bromide staining. 
2.2.2 Site-directed mutagenesis of soluble N-domain 
2.2.2.1 Design of mutagenic primers 
One hundred percent complementary primer pairs were designed containing two key features: 
the mismatch containing the desired codon change and silent mutation(s) that introduces an 
additional restriction site into the primer incorporated plasmid. Primers were designed 
according to Stratagene guidelines (Papworth et al., 1996) and synthesised by the Inqaba 
DNA Synthesis Unit (Inqaba Biotech Ltd.). Primers are detailed in Table 2.2. The two primer 
sets for Y369F and R381E were used in sequential mutagenesis runs for the double mutant 
YR/FE; while a new primer, eliminating the PvuII site of the S357V primer template was 
used to generate ST/VV. 
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Table 2.2: Details of primers utilised for site-directed mutagenesis. Primers were designed 
using Stratagene guidelines. The codon changed is indicated in bold lower case letters and the 
restriction enzyme recognition sequence is underlined. In the case of ST357,358VV primer; 
primer design resulted in the removal of the PvuII restriction site of the S357V template. 
Subsite Mutation Sequence (5´→3´) Tm (°C) 
Screening 
enzyme 
S2 
Y369F CCATATACAGTACttcCTGCAATACAAAGATCTGCCCG 74.2 BglII 
R381E GGATCTGCCTGTATCCTTGCGTgagGGGGCCAACC 76.6 BfuI 
T496V GCTAAGTTTCATGTTCCAAATGTGgtaCCATACATCAGG 75.9 KpnI 
S2´ 
E262S GCCCAGAGCTGGtcaAATATTTACGACATGGTGGTGCC 74.8 SspI 
D354E CGGGTCACGATGgagCAGCTGTCCACAGTGCACC 82.3 PvuII 
S357V CGATGGACCAGCTGgtcACAGTGCACCATGAGATGG 78.3 PvuII 
T358V CGATGGACCAGCTGTCCgtaGTGCACCATGAGATGG 78.3 PvuII 
ST357,358VV CGATGGACCAGCTCGTCgtaGTGCACCATGAGATGG 81.1 
PvuII 
removed 
E431D GCTAAAAATGGCACTGgacAAAATTGCATTCCTGCC 75.4 BsmI 
 
 
2.2.2.2 Site-directed mutagenesis approach 
Reactions were performed using a modified DpnI method (Quick Change
®
 Site-directed 
mutagenesis, (Papworth et al., 1996). Final concentrations of 0.2 µM primers, 0.4 mM 
dNTPs (Sigma-Aldrich Co.), 5% DMSO (Merck Ltd) and 3 units high fidelity Pfu 
polymerase (Roche Pharmaceuticals) with a total mass of 100 ng pBS-D629 were used in 
each mutagenic reaction. Polymerase chain reactions were carried out with the following 
thermal cycling parameters: denaturation at 94°C (5 min); followed by 16 cycles of 94°C 
(30 s), 55°C (30 s), 72°C (12 min); final elongation at 72°C (20 min). Aliquots of reactions at 
various Mg
2+
 concentrations (for optimal polymerase activity and primer specificity) 
(McPherson, 1990) underwent agarose gel electrophoresis and visualised by ethidium 
bromide staining. Mutagenic runs showing the greatest specific amplification were selected 
and digested with 30 units of methylation specific restriction enzyme DpnI (Fermentas Life 
Sciences) for 4 hours at 37°C to remove remaining template DNA. This was followed by 
transformation of an aliquot of PCR product reaction mixture into competent DH5α E. coli 
cells and transformants plated onto ampicillin agar plates (Appendix A1).   
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2.2.2.3 Mutation confirmation 
Resistant pBS-D629 mutant clones were picked and grown overnight in ampicillin containing 
media. Plasmid DNA was crudely isolated, digested with the appropriate restriction enzyme 
and visualised with agarose gel electrophoresis (Appendix A1). Positively incorporated 
mutants were identified by differences in DNA banding patterns compared to template DNA. 
The presence of the desired mutations, and absence of spurious introductions, was confirmed 
by nucleotide sequencing of the entire D629 coding region using internal D629 and flanking 
vector (T3 and T7) primers (sequencing performed by DNA Sequencing Unit, Department of 
Molecular and Cell Biology, UCT). 
2.2.3 Cloning of mutant D629 constructs into mammalian expression vector pcDNA 3.1(+) 
The cloning strategy served to take the D629 coding region present in a sequencing vector 
and successfully incorporate it into another vector effective in mammalian protein expression 
(Figure 2.1). Approximately 300 ng of each successfully mutated pBS-D629 template was 
doubly digested with 15 units EcoRI and 10 units XbaI. This allowed for the expulsion of the 
D629 insert out of the sequencing vector. Following enzymatic digestion, fragments were 
separated out through agarose gel electrophoresis, visualised and inserts of the correct size 
excised. Excised insert was purified from the agarose gel using the Wizard
®
 SV Gel and PCR 
Clean-Up System (Promega Ltd) with supplied protocol and resuspended in 50 µl nuclease 
free dH2O. Singly digested pBS-D629 mutants were produced to control for ligation 
experiments. Approximately 400 ng of empty vector pcDNA 3.1(+) (Invitrogen Corp.) was 
doubly digested as above to provide suitable sites for ligation of the insert in the correct 
orientation. Ligation reactions were set up using a ratio of 1:3 (vector:insert) in the presence 
of T4 DNA ligase (Fermentas Life Sciences) for several hours at room temperature. Ligation 
reactions were transformed into competent DH5α E. coli and transformants grown on 
ampicillin selective agar plates (Appendix A1). Screening with cloning enzymes and 
restriction enzyme sites mutagenically produced allowed for the identification of positive 
clones containing the mutated insert in pcDNA 3.1(+), thus pcDNA-D629. Identified positive 
constructs were bulk purified using a medium scale plasmid preparation kit (Qiagen Corp.). 
Prior to transfection, correct mutation and purity of each plasmid was confirmed by 
restriction enzyme digestion and subsequent agarose gel electrophoresis. 
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Figure 2.1: A schematic representation of the cloning strategy employed for incorporation of 
D629 mutant coding regions into mammalian expression vector pcDNA 3.1 (+). pBS 
(Invitrogen Corp.) containing the wild-type D629 coding region (hashed bar) was mutated to 
codons of interest via site-directed mutagenesis and confirmed by nucleotide sequencing. The 
D629 coding region was excised from pBS-D629 through double digestion of cloning 
enzymes EcoRI and XbaI (Fermentas Life Sciences). Pure insert was ligated with prepared 
vector pcDNA 3.1(+) (previously EcoRI and XbaI doubly digested, Invitrogen Corp.) to 
produce pcDNA-D629 constructs. Incorporation and orientation of the D629 insert were 
confirmed by restriction enzyme digests. 
 
2.2.4 Mammalian cell expression of N-domain enzymes 
Chinese hamster ovary (CHO) mammalian cell line CHO-K1 was used as the model system 
for transfection and expression of N-domain enzymes. CHO-K1 cells were cultured at 37°C, 
5% CO2 and 80% relative humidity levels. 
CHO-K1 cells were grown to 60% confluency in 100 mm transfection dishes (all tissue 
culture dishes and flasks supplied by Nunc Ltd) and transfected using the calcium phosphate 
Profection
®
 Mammalian Transfection System (Promega Corp.) according to the 
manufacturer’s protocol. Briefly, fresh growth medium (constituents of tissue culture medium 
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employed detailed in the Appendix A2) was applied to the untransfected cells 3 hours prior to 
transfection. Approximately 15 µg of pcDNA-D629 construct was finely precipitated by 
dropwise addition of the DNA solution to CaCl2 (as per manufacturer’s guidelines). 
Following a 30 minute room temperature incubation of the DNA precipitate, the DNA 
suspension was added dropwise to the cultured cells and incubated at culturing conditions for 
about 4 hours. To increase transfection efficiencies, cells underwent exposure to glycerol 
shock solution for 2 minutes followed by extensive washing with wash solution (constituents 
outlined in the Appendix A2) and subsequent replacement of growth medium. 
Twenty four hours after transfection, normal growth medium was replaced with growth 
medium containing mammalian anti-biotic geneticin (G418; 0.9 mg/ml, Sigma-Aldrich Co.). 
Colonies showing resistance to G418 were picked and grown in 12 well plates, with high 
activity clones being selected based on ACE activity via Z-Phe-His-Leu (Z-FHL) assay 
(Section 2.2.5). Highest expressers of each construct were seeded from 12 well plates and 
grown to confluency in T-175 cm
2
 flasks; followed by addition of harvesting medium 
(Appendix A2). Medium was harvested every 72 hours and stored at -20°C until purification. 
2.2.5 Z-Phe-His-Leu assay 
The cleavage of ACE substrate Z-FHL is useful in determining the extent of ACE activity 
and expression in a given cell culture system or protein solution and was performed as 
previously described (Friedland and Silverstein, 1976; Schwager et al., 2006). Briefly, 5 µl of 
medium solution was added to 30 µl of a 1 mM Z-FHL (Bachem Ltd) in phosphate buffer 
(100 mM KHPO4/KH2PO4 pH 8.3, 300 mM NaCl, 10 µM ZnSO4) on ice in triplicate in a 96-
well plate. This enzyme-substrate mixture was incubated at 37°C for 20 minutes and stopped 
by the addition of 120 µl 0.4 M NaOH. Derivitisation of the liberated His-Leu moiety 
commenced with the addition of o-pthaldialdehyde (Sigma-Aldrich Co., 24 mg/ml in 
methanol) and the subsequent mixture incubated at room temperature for 10 minutes. 
Derivitisation was stopped through the addition of 30 µl 3 M HCl and fluorescence intensities 
measured at λex= 360 nm and λem= 485 nm using a fluorescence spectrophotometer (Varian 
Inc.). Enzymatic activity was calculated through the use of a His-Leu standard curve (section 
3.2.4.1 and Appendix A4). 
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2.2.6 Purification of N-domain enzymes 
Lisinopril, a potent ACE inhibitor, coupled by its free P1´ lysine to sepharose beads was 
employed to conduct a one-step affinity chromatography purification protocol (El Dorry et 
al., 1982; Bull et al., 1985). Medium harvests were defrosted, pooled and NaCl added to 
bring the final salt concentration to 800 mM NaCl to ensure sufficient binding of the 
N-domain to the lisinopril beads (Deddish et al., 1994). The lisinopril-sepharose affinity 
column was first washed with wash buffer (20 mM HEPES pH 7.5, 800 mM NaCl, 10 µM 
ZnSO4) for 20 minutes. The salted harvest medium was loaded on the prepared column and 
allowed to pass through. Once the harvest medium had been loaded onto the column, the 
column was washed overnight with wash buffer to remove unbound material. Elution 
proceeded with the washing of the column with elution buffer (50 mM borate pH 9.5) and 
eluted fractions collected. Fractions displaying ACE activity (in a Z-FHL assay, section 2.2.5) 
were pooled into SnakeSkin
®
 pleated dialysis tubing (Pierce Biotechnology Ltd) and placed 
into dialysis buffer 1 (5 mM HEPES pH 7.5, 0.05 mM PMSF (in ethanol)) at 4°C for 6 hours. 
The pooled dialysed enzyme solution was then placed into dialysis buffer 2 (50 mM HEPES 
pH 7.5, 0.05 mM PMSF (in ethanol)) and dialysed overnight at 4°C. Protein concentration 
after dialysis was determined via a Bradford assay (Bradford, 1976) using BioRad protein 
reagent (BioRad Laboratories Inc.) and albumin as a standard. Protein purity was assessed via 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% 
acrylamide gel and stained with Coomassie stain (Appendix A2). Wild type C-domain was 
purified in a similar manner with the exception of lower NaCl concentrations in the wash 
buffer (buffer contained 500 mM NaCl). 
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2.3 Results 
2.3.1 Preparation of pBS-D629 
The coding region of the N-domain of ACE had previously been inserted into the plasmid 
pBlueScript SK+ (Balyasnikova et al., 2003). Transformation and plasmid DNA isolation 
allowed for identification of a pBS-D629 clone. Double digestion with cloning enzymes 
EcoRI and XbaI reveals the vector (2.9 kb) and D629 coding region (2.0 kb) after agarose gel 
electrophoresis (Figure 2.2). 
 
 
Figure 2.2: Restriction enzyme analysis of pBS-D629 mutagenesis construct. Unmutated 
pBS-D629 was digested with XbaI or doubly with EcoRI and XbaI to confirm plasmid and 
insert sizes. A plasmid size of 4.9 kb, vector of 2.9 kb and insert of 2.0 kb were confirmed. 
Lane 1, molecular weight marker (O’GeneTM Ruler DNA Ladder Mix, Fermentas); lane 2, 
pBS-D629 XbaI digest; lane 3, pBS-D629 EcoRI/XbaI double digest. 
 
2.3.2 Site-directed mutagenesis 
Using mutagenic primers and cycling parameters as outlined in Methods (section 2.2.2), a 
clear amplicon at predicted plasmid size (4.93 kb) for all mutant D629 constructs was 
obtained (Figure 2.3). 
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Figure 2.3: A representative gel indicating site-directed mutagenesis products of mutations 
R381E (lanes 2-4); S357V (lanes 5-7) and T358V (lanes 8-10). pBluescript SK(+) containing 
wild type N-domain (D629), pBS-D629, was used as a template and mutagenic constructs 
amplified using high fidelity Pfu DNA polymerase. Expected product migrates at a size of 
approximately 5 kb. Lane 1, molecular weight marker (EcoRI/HindIII λ DNA); lane 2, 
R381E 2 mM MgCl2 run; lane 3, R381E 3 mM MgCl2 run; lane 4, R381E 4 mM MgCl2 run; 
lane 5, S357V 2 mM MgCl2 run; lane 6, S357V 3 mM MgCl2 run; lane 7, S357V 4 mM 
MgCl2 run; lane 8, T358V 2 mM MgCl2 run; lane 9, T358V 3 mM MgCl2 run; lane 10, 
T358V 4 mM MgCl2 run. Products from lanes 3, 5 and 8 were selected for further screening. 
    
Mutagenic reactions showing the greatest visualised mplification were digested with DpnI, 
transformed, plasmid DNA isolated of selected clones and digested with the appropriate 
restriction enzyme that contained the newly introduced mutagenic primer restriction site. 
Screened pBS-D629 mutant constructs displayed a DNA banding pattern different to that of 
wild type pBS-D629 with sizes as predicted by computational methods (DNAMAN v. 4.13, 
Lynnon Biosoft, 1994).    
Nucleotide sequencing of the entire D629 coding region confirmed the correct introduction of 
codon change and silent restriction site without any spurious mutations incorporated. 
2.3.3 Cloning of mutant D629 constructs into mammalian expression vector pcDNA 3.1(+) 
and plasmid confirmation 
Confirmed mutant coding regions of D629 in pBS-D629 were excised through double 
endonuclease digestion with cloning enzymes EcoRI and XbaI and isolated fragments 
inserted into mammalian expression vector pcDNA 3.1(+) as described above (section 2.2.3). 
Screening of pcDNA-D629 mutants using appropriate restrictions enzymes (those 
incorporated into D629 during mutagenesis) revealed banding patterns that indicated the 
desired vector, the presence of the incorporated primer and correctly orientated insert. 
21.2 
5.1 
4.9 
4.3 
2.0 
1.9 
Size (kb) 1 3 4 5 6 7 8 9 10 2 
4.93 kb 
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Banding patterns of mutant plasmids predictably differed compared to wild type digests of 
the corresponding screening endonuclease (Figures 2.4-2.6). Double S2´ construct ST/VV 
contained two consecutive mutations in the same coding region and required the removal of 
the PvuII from the S357V template to facilitate mutation screening. Thus, restriction 
screening of pcDNA-ST/VV with enzyme PvuII differed from S357V and T358V mutants and 
had the same banding pattern as that of unmutated plasmid (Figure 2.5). Positively identified 
plasmids were individually bulk purified for transfection. 
 
 
Figure 2.4: Confirmation of pcDNA-D629 mutations present in the N-domain S2 subsite. 
Successfully cloned mutant D629 coding regions underwent restriction enzyme screening 
with endonucleases that recognise the primer introduced restriction site to confirm both the 
correct vector size and presence of the desired mutation. Lane 1, molecular weight marker 
(O’GeneTM Ruler DNA Ladder Mix, Fermentas); lane 2, unmutated wild type pcDNA-D629 
BglII digest; lane 3, pcDNA-Y369F BglII digest; lane 4, unmutated wild type pcDNA-D629 
BfuI digest; lane 5, pcDNA-R381E BfuI digest; lane 6, pcDNA-YR/FE BglII digest; lane 7, 
pcDNA-YR/FE BfuI digest; lane 8, unmutated wild type pcDNA-D629 KpnI digest; lane 9, 
pcDNA-T496V KpnI digest. Construct pcDNA-YR/FE contains both Y369F and R381E 
mutations in the same D629 coding region. 
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Figure 2.5: Confirmation of pcDNA-D629 hydrophobic mutations present in the N-domain 
S2´ subsite. Restriction enzyme screens were performed as in Figure 2.4. Lane 1, molecular 
weight marker (O’GeneTM Ruler DNA Ladder Mix, Fermentas); lane 2, unmutated wild type 
pcDNA-D629 PvuII digest; lane 3, pcDNA-S357V PvuII digest; lane 4, pcDNA-T358V PvuII 
digest; lane 5, pcDNA-ST/VV PvuII digest. Construct pcDNA-ST/VV contains both S357V and 
T358V mutations in the same D629 coding region. Primer incorporation resulted in the loss 
of the PvuII (2131) site of the S357V template. 
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Figure 2.6: Confirmation of pcDNA-D629 mutations of acidic amino acids present in the 
N-domain S2´ subsite. Restriction enzyme screens were performed as in Figure 2.4. Lane 1, 
molecular weight marker (O’GeneTM Ruler DNA Ladder Mix, Fermentas); lane 2, unmutated 
wild type pcDNA-D629 SspI digest; lane 3, pcDNA-E262S SspI digest; lane 4, unmutated 
wild type pcDNA-D629 PvuII digest; lane 5, pcDNA-D354E PvuII digest; lane 6, unmutated 
wild type pcDNA-D629 BsmI digest; lane 7, pcDNA-D629 BsmI digest.  
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2.3.4 Expression and purification of enzymes 
Successfully produced plasmids were transfected into CHO-K1 cells using a calcium-
phosphate precipitation protocol as outlined in section 2.2.4. Transfection of pcDNA-D629 
plasmids yielded high expressing clones that had detectable Z-FHL hydrolysis activity in the 
culture medium (Table 2.3). Medium activity of untransfected CHO-K1 cells was negligible. 
Post lisinopril affinity chromatography (section 2.2.6), yields of protein per litre of harvest 
medium were calculated. Protein yields were variable between enzymes ranging from 0.8 to 
17.9 mg.L
-1
. Several N-domain enzymes (R381E, T496V, D354E and T358V) displayed 
better expression than wild type enzymes while other derivatives (YR/FE and ST/VV) 
showed marked reduction in expression profile. In all cases there was sufficient enzyme to 
proceed with kinetic analysis (presented in Chapters 3 and 4). 
Table 2.3: Expression levels of C-domain, N-domain and N-domain protein derivatives. 
Transfection and expression was performed as detailed in section 2.2.4. Protein yield was 
calculated post-purification. 
Subsite Enzyme Activity (mU.ml
-1
 medium) Protein yield (mg.L
-1
 medium) 
- 
N-domain 163.4 9.06 
C-domain 156.9 2.12 
S2 
Y369F 326.0 7.88 
R381E 191.7 13.6 
YR/FE 74.49 0.90 
T496V 360.4 19.1 
S2´ 
E262S 215.9 10.2 
D354E 414.9 12.6 
S357V 45.2 2.35 
T358V 412.7 17.9 
ST/VV 50.1 0.81 
E431D 157.0 5.30 
 
All purified enzymes were subjected to SDS-PAGE and visualised with Coomassie staining 
(section 2.2.6). The predicted molecular mass of unglycosylated N-domain is 72.25 kDa and, 
taking into account glycosylation (approximately 30%), was predicted to result in a total mass 
of approximately 90 kDa (Deddish et al., 1994; Gasteiger et al., 2003). Visualised protein 
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bands revealed enzymes migrating at the correct predicted size, in agreement with a previous 
publication expressing soluble N-domain in CHO cells (Rice et al., 2004), and in a 
homogenous state (Figure 2.7). 
 
 
Figure 2.7: Representative acrylamide gels indicating enzyme size and purity. Approximately 
10 µg of protein was electrophorised at 50 mA in a 10% denaturing acrylamide gel until 
suitable separation was achieved. The gel was stained with Coomassie Brilliant Blue and 
destained with destaining solution as described in Methods and Appendix A2. Lane 1, low 
molecular weight marker (sizes displayed in kDa, BioRad); lane 2, purified N-domain; lane 3, 
purified Y369F; lane 4, purified R381E; lane 5, purified YR/FE; lane 6, purified E431D; lane 
7, purified T496V. In all cases a single stained band of approximately 90 kDa was observed. 
Each gel underwent electrophoresis with a molecular marker and aligned. 
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2.4 Discussion 
Site-directed mutagenesis is a powerful molecular biology technique effective in the 
production of DNA constructs with desired mutations. Many technique variations have been 
designed ranging from single nucleotide substitution protocols to recombinant approaches 
whereby large fragments are inserted in cassette-like fashion (McPherson, 1990). While 
original procedures required single stranded DNA as a template and in vitro completion of 
the complementary strand, use of PCR methodologies allowed for the use of double stranded 
DNA as a starting template, permitting the use of standard plasmids from organisms other 
than viruses. Identification of primer incorporated plasmids has traditionally taken four 
approaches; namely restriction selection, restriction purification, the use of uracil-containing 
vectors and recognition of phosphorothioate containing plasmids (from the original primer 
set) (McPherson, 1990).  In this study, extensive digestion with methylation specific 
endonuclease DpnI prior to screening digest removed almost all methylated parental DNA 
(Papworth et al., 1996). This provided simplicity of screening whereby most of the 
transformants screened were positive for the desired mutation. Restriction selection remains 
one of the simplest approaches in identification of positive clones without the use of radio 
labelled probes and is considerably more cost effective than total gene synthesis (Carter, 
1986).   
A simple cloning strategy allowed for confirmed mutants to be successfully cloned into a 
mammalian expression vector through the unique restriction sites of EcoRI and XbaI in the 
correct insert orientation. Such a cloning strategy had been designed previously to allow for 
uncomplicated orientation of the insert in the vector (Balyasnikova et al., 2003; Corradi et al., 
2006). All expression plasmids were confirmed by restriction enzyme digestion and 
transfected into CHO-K1 cells.  
Heterologous protein expression has allowed the bulk expression of numerous recombinant 
proteins that otherwise would require laborious extraction procedures and large amounts of 
tissue to obtain suitable quantities of enzyme. A number of expression systems have been 
developed with each having its own set of advantages and disadvantages (reviewed in (Yin et 
al., 2007). Whilst expression in the E. coli bacterial system is considered simplest and most 
cost effective, such a system is not appropriate for the expression of ACE domains due to 
prokaryotes lacking the molecular machinery for N-linked glycosylation and chaperone 
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mediated protein folding (Yin et al., 2007; Mus-Veteau, 2002). Thus, eukaryote cells are 
required for ACE expression. Indeed, ACE has previously been reported to be expressed in 
E. coli but inactive while expression in yeast Pichia Pastoris or cancer cell line HeLa 
produced active enzyme albeit with different glycosylation patterns (Sadhukhan and Sen, 
1996; Williams et al., 1997). CHO cells (along with other mammalian cell lines) provide the 
appropriate machinery for the expression of ACE and this system has been used in our 
research group to produce ACE proteins in amounts sufficient for crystallisation studies 
(Natesh et al., 2003; Gordon et al., 2003; Corradi et al., 2006).  This optimised system was 
sufficient for the need of relatively small amounts of protein required for this study. 
Transfection of the CHO-K1 cell line produced stable cell lines expressing assay detectable 
amounts of enzyme activity, with higher culture medium activity generally corresponding to 
higher protein yields. Variable expression was obtained for protein derivatives with some 
active site mutants resulting in higher expression than that of wild type controls while both 
N-domain double mutants had considerably lower activities and yields. Although the 
conversion of one or more amino acids could result in a more (or less) stable protein 
structure; these data are most likely due to variable transfection efficiencies. This is suggested 
since enzymes (with the exception of ST/VV) display comparable catalytic efficiencies to 
wild-type controls with substrate Abz-Phe-Arg-Lys(Dnp)-Pro (Chapter 3). The ST/VV 
mutant could have lowered medium activity probably due to decreased overall catalytic 
ability (presented in Chapter 3). The C-domain enzyme displayed similar activity but reduced 
yield when compared to the N-domain and is most likely due to its increased catalytic 
efficiency with the substrate Z-FHL (Chapter 3). Thus, less enzyme is required for similar 
activities.   
Purification of both isoforms of ACE has involved purification techniques of ion exchange 
and size exclusion (Cheung et al., 1980; Stewart et al., 1981; Ronchi et al., 2005), the use of 
ACE specific antibodies (Lanzillo et al., 1980) and affinity chromatography using modified 
ACE inhibitor structures (Harris et al., 1981; El Dorry et al., 1982; Pantoliano et al., 1984; 
Bull et al., 1985). Affinity chromatography allows ACE to be purified to much higher fold 
purification from tissue and plasma in only a few steps. Such an approach can also be used, 
as in this setting, in the purification of recombinant ACE from tissue culture medium in a 
single purification step. In each case, N-domain and mutant enzymes were purified to 
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homogeneity as observed by gel electrophoresis, thus yielding sufficiently pure protein for 
subsequent kinetic analyses.    
In summary, implicated residues in the N-domain S2 and S2´subsites were converted to 
corresponding C-domain counterparts via site-directed mutagenesis and confirmed by 
nucleotide sequencing of the N-domain coding region. An effective cloning strategy allowed 
for incorporation of the D629 coding region in a mammalian expression vector and plasmids 
were transfected. Variable protein expression was observed and, following affinity 
chromatographic purification, in all cases there was sufficient protein for the required 
substrate and inhibitor kinetic analysis.  
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Chapter 3 
Mutations in the N-domain and their effects on substrate processing 
 
3.1 Introduction 
Somatic ACE is able to cleave a variety of physiologically relevant peptides (reviewed in 
Chapter 1). In addition, despite 90% sequence identity between the N- and C-domain active 
sites (Soubrier et al., 1988), domain substrate specificity exists for a number of these 
peptides. In vivo mouse studies have demonstrated the primary role of the C-domain in AngI 
conversion, while inactivation of the N-domain through gene targeting or selective inhibition 
resulted in elevated AcSDKP levels (Junot et al., 2001; Fuchs et al., 2004; Fuchs et al., 
2008). 
Several previous publications sought to define the determinants of N-selective substrate 
processing. Such analysis involved the generation of AcSDKP analogues and their 
subsequent effects on N-selective processing (Michaud et al., 1997; Michaud et al., 1999; 
Araujo et al., 2000). Mutational analyses of unique amino acids present in the enzyme active 
subsites and the consequent catalytic effects have not been performed with regards to 
N-domain substrate processing.  
Five substrates relevant to this study are outlined below.   
Abz-Phe-Arg-Lys(Dnp)-Pro (Abz-FRK(Dnp)P) is a fluorogenic substrate that is processed 
with similar ability by both domains (Araujo et al., 2000). Thus, conversion to N-domain 
residues to their corresponding C-domain counterparts should not abolish enzymatic ability 
towards this substrate. This is useful in assessing the extent of inhibition by small molecule 
inhibitors toward mutant N- and C-domain enzyme derivatives without drastic changes in 
substrate cleavage activity (to be presented in Chapter 4). 
Z-Phe-His-Leu (Z-FHL) and hippuryl-His-Leu (HHL) are short, synthetic and relatively 
inexpensive ACE substrates. Each domain displays differing kinetic capacities for these two 
substrates; HHL is a relatively poor substrate of the N-domain compared to C-domain 
processing while Z-FHL is the better bound and cleaved of the two substrates for both 
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domains (Wei et al., 1991; Danilov et al., 2008). This suggests that unique residues present in 
the N-domain contribute to the less efficient hydrolysis of HHL. 
AcSDKP, and its internally quenched fluorogenic derivative Abz-SDK(Dnp)P, have been 
shown to be the substrates most specifically cleaved by the N-domain (Rousseau et al., 1995; 
Araujo et al., 2000). Synthetic substrate analogues of the AcSDKP template and their 
catalysis by the N- and C-domains implicated the substrate P2 (N-acetyl-Ser) group in being a 
predominant determinant for substrate selective processing (Michaud et al., 1999; Araujo et 
al., 2000). Thus, unique residues in the N-domain could be providing distinct interactions 
with substrate molecules to allow for differential domain substrate processing preferences. 
Previous characterisation of AcSDKP binding and hydrolysis has involved the use of 
recombinant full length human sACE with inactivated domains (Rousseau et al., 1995) or 
individual soluble domains of human ileal ACE (N-domain) and rabbit tACE (C-domain) 
(Deddish et al., 1996). Importantly, no kinetic characterisation of the soluble human N- and 
C-domains has been performed with this peptide. This is important due to many experiments 
having been performed with the soluble human forms, especially with inhibitor binding 
(Corradi et al., 2006; Nchinda et al., 2006a; Nchinda et al., 2006b; Watermeyer et al., 2008). 
Furthermore kinetic characterisation of AcSDKP processing has involved the use of paper 
electrophoresis or high pressure liquid chromatography (HPLC), both of which are time 
consuming and lack the high throughput approach required for screening numerous mutant 
enzymes and novel inhibitors. Alternatively, since AcSDKP has a protected N-terminus, an 
appropriate derivatising agent that could recognise the formation of a new N-terminus could 
allow for the quantification of kinetic parameters. Such an approach, using N-acetylated AngI 
with fluorescamine, has been reported and could be used to assess AcSDKP processing in a 
plate adapted assay (Conroy and Lai, 1978).    
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The objectives for the assessment of residue contribution to selective substrate processing 
were as follows: 
1. To kinetically characterise N-domain active site mutants and wild type N-domain 
hydrolysis of the non-domain selective substrate Abz-FRK(Dnp)P. 
2. To utilise the Z-FHL/HHL ratio to identify residues potentially contributing to poor 
HHL cleavage by the N-domain; and subsequent kinetic characterisation of such 
mutants with Z-FHL and HHL. 
3. To kinetically assess the effects of active site mutations on the binding and hydrolysis 
of Abz-SDK(Dnp)P. 
4. To establish a novel assay for AcSDKP cleavage and to subsequently perform kinetic 
analyses with the human N- and C-domains of ACE.  
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3.2 Methods 
3.2.1 Active enzyme concentration determination 
While traditional methods are useful for quantification of protein concentration, such 
approaches provide no quantification of active enzyme amount. This information is necessary 
because of degradation after purification due to long term storage and/or protein instability 
due to mutation (Knight, 1995). Assuming a 1:1 binding ratio, incubation of enzyme with a 
potent inhibitor at varying molar ranges with subsequent activity assay can provide an 
indication of remaining enzyme molar amount and has been successfully used to confirm 
active ACE concentrations (Binevski et al., 2003; Rice et al., 2004; Skirgello et al., 2005). A 
modified Z-FHL assay (section 2.2.5) was employed for the determination of active enzyme 
concentration. Briefly, a serial dilution of ACE inhibitor lisinopril was incubated with 40 nM 
enzyme in phosphate incubation buffer (100 mM KHPO4/KH2PO4 pH 8.3, 300 mM NaCl, 10 
µM ZnSO4, 1 mg/ml albumin) for 120 minutes at room temperature. Following 20 µl aliquots 
of the enzyme-inhibitor complex in triplicate, the enzyme-inhibitor complex and substrate 
(2 mM Z-FHL) were separately pre-warmed to 37°C and assay commenced with addition of 
20 µl substrate. After 5 minutes incubation the assay was stopped, free His-Leu dipeptides 
derivatised and fluorescence determined as described previously (section 2.2.5). Data was 
analysed for the determination of equimolar inhibitor required to achieve 0% enzyme activity 
and the active enzyme concentration therefore determined (Figure 3.1). 
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Figure 3.1: A representative curve displaying the calculation of active enzyme in a given 
buffer storage solution. Assays of the enzyme-inhibitor complexes were performed as 
described in section 3.2.1. Percentage remaining activity is plotted against the molar ratio of 
inhibitor to enzyme and linear regression analysis performed on the linear range. The 
x intercept of the extrapolated curve is taken as the theoretical amount of inhibitor for zero 
remaining enzyme activity.   
 
3.2.2 Internally quenched fluorogenic substrates: Construction of standard curve and 
determination of correction values 
3.2.2.1 Construction of Abz-Gly standard curve 
A free donor o-aminobenzoic acid fluorescent group coupled to Gly, Abz-Gly (Bachem Ltd.), 
was used to correlate fluorescence intensity to free donor group amount. A 2 µM stock of 
Abz-Gly was serially diluted in Tris assay buffer (50 mM Tris-HCl pH 7.0, 100 mM NaCl, 
10 µM ZnCl2) and 300 µl volumes aliquoted in triplicate into a 96-well plate (0-600 pmols). 
Fluorescence intensities were determined using 320 nm and 420 nm excitation and emission 
wavelengths respectively using a Cary Eclipse spectrofluorimeter (Varian Inc.) and linear 
regression analysis performed (v 4.01, GraphPad Prism
®
) (see Appendix A4). 
3.2.2.2 Determination of correction values 
3.2.2.2.1 The “inner filter effect” 
Fluorescence resonance energy transfer (FRET) peptides have been successfully utilised for 
the continuous monitoring of activity of numerous enzymes, including ACE (Dive et al., 
1999; Araujo et al., 2000; Wang et al., 1993). FRET peptides emit a detectable fluorescence 
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upon separation of the donor (donor group used in this study: o-aminobenzoic acid, Abz) and 
acceptor (acceptor group used in this study: 2,4-dinitrophenyl, Dnp) groups through 
proteolytic activity. However, higher substrate concentrations result in less distance between 
uncleaved substrate and Abz-product molecules resulting in product quenching by 
neighbouring uncleaved groups and thus a decrease in observed fluorescence signal. Such an 
effect on fluorescence observation hampers the accurate determination of enzymatic kinetic 
parameters and is generally referred to as the ―inner filter effect‖ (IFE) (Liu et al., 1999; 
Araujo et al., 2000). Correction of the IFE requires empirical methods. 
3.2.2.2.2 Empirical determination of correction values 
A simple empirical procedure for the correction of the IFE in a plate assay has been described 
by (Liu et al., 1999). Baseline fluorescence readings of different Abz-SDK(Dnp)P substrate 
concentrations (0-50 µM) were measured as above (Section 3.2.2.1) in a 297 µl volume in 
Tris assay buffer. Three microlitres of 50 µM Abz-Gly was added to the substrate solutions, 
mixed thoroughly and fluorescence reread as before. Ratios of change in fluorescence with 
increasing substrate concentration compared to zero substrate were calculated and a 
non-linear equation used to fit the values up to 50 µM substrate. This correction curve was 
used to correct all further kinetic experiments with Abz/Dnp donor/acceptor group substrates. 
3.2.3 Non-selective fluorogenic substrate Abz-FRK(Dnp)P: Kinetic parameters 
Variable volumes of a 50 µM Abz-FRK(Dnp)P substrate solution were aliquoted in triplicate 
into a 96-well plate on ice. Enzyme solution in HEPES assay buffer (50 mM HEPES pH 6.8, 
200 mM NaCl, 10 µM ZnCl2) was added to bring the final assay volume to 300 µl and 
0.2 pmols enzyme. This buffer system was used to mimic the conditions required for RXP407 
binding kinetics assays (described in Chapter 4). Fluorescence intensities were monitored 
continuously at ambient temperature (λex= 320 nm; λem= 420 nm) for 20 minutes. Initial 
changes in intensities over time were corrected with correction values and converted to 
reaction velocities by use of the standard curve (section 3.2.2.1). Kinetic constants Km and kcat 
were determined by the direct linear plot method (Eisenthal and Cornish-Bowden, 1974). 
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3.2.4 Synthetic substrates: Z-FHL and HHL 
3.2.4.1 Construction of His-Leu standard curve  
Construction of a standard curve of enzymatic cleavage product of Z-FHL and HHL; 
dipeptide His-Leu (HL) was carried out as described by (Schwager et al., 2006). 
Commercially available HL (Sigma-Aldrich Co.) was dissolved in dH2O to yield a 5 mM HL 
stock solution and subsequently diluted to a 0.5 mM working solution in phosphate buffer 
(100 mM KHPO4/KH2PO4 pH 8.3, 300 mM NaCl, 10 µM ZnSO4). HL working solution was 
diluted in a 96-well plate with phosphate buffer producing increasing amounts of HL per 
30 µl. The assay for HL fluorescence was carried out as described in section 2.2.5 and 
commenced with the addition 0.4 M NaOH. Change in fluorescence was correlated to 
nanomoles HL by using linear regression analysis as in section 3.2.2.1 (see Appendix A4).  
3.2.4.2 Z-FHL/HHL ratios 
Differences in catalysis of Z-FHL and HHL by the N- and C-domains allow the ratio of rates 
of hydrolysis of these two substrates to be used to describe ―domain-likeness‖. Due to the 
N-domain cleaving HHL poorly compared to the C-domain, one would expect a higher 
Z-FHL/HHL ratio for the N-domain and mutation of important substrate binding residues 
causing a decrease in ratio. Z-FHL/HHL assays were performed as described in (Danilov et 
al., 2008). Three microlitres of purified enzyme was added to 30μl of either Z-FHL (1 mM) 
or HHL (5.7 mM) (Appendix A3) in phosphate buffer triplicate in a 96-well plate. The 
enzyme-substrate solution was incubated at 37°C for 20 minutes followed by addition of 
120µl of 0.4 M NaOH to stop catalysis. Derivitisation, subsequent termination of 
derivitisation and fluorescence intensities determination were performed as outlined in 
section 2.2.5. Fluorescent values were converted into enzymatic activity and the ratio of 
activities (Z-FHL/HHL) of the enzyme towards the two substrates was calculated. 
3.2.4.3 Kinetic parameter determination of Z-FHL and HHL hydrolysis 
A modified Z-FHL assay was employed to assess the kinetic behaviour of several mutants 
that displayed changes in Z-FHL/HHL ratio towards a C-domain-like ratio. Two N-domain 
mutant enzymes showing the greatest shift towards the C-domain ratio (Y369F and ST/VV) 
were selected for further kinetic analysis.  Five microlitres of enzyme stock solution in 
phosphate buffer was aliquoted in triplicate into a 96-well plate and pre-warmed to 37°C. The 
assay commenced through the addition of 30 µl pre-warmed substrate (either Z-FHL or HHL) 
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at varying concentrations. Following incubation at 37°C for 15 minutes, 120 μl of 
0.4 M NaOH was added to stop the enzymatic reaction. Subsequent assay steps were carried 
out as described previously (section 2.2.5). Enzymatic reaction rates were calculated using a 
standard curve correlating moles HL to fluorescence intensities and kinetic parameters (kcat 
and Km) determined using Michaelis-Menten kinetic curves drawn by nonlinear regression 
analysis (v 4.01, GraphPad Prism
®
). 
3.2.4.4 Molecular docking of Z-FHL and HHL into the N- and C-domains 
Molecular modelling experiments to dock substrates Z-FHL and HHL into the N- and 
C-domain active sites were conducted in a manner described previously using INSIGHT II 
(v 98.0, Accelrys Inc.) (Corradi et al., 2006). Crystal structures of the N-domain (PDB 
accession code 2C6N containing RXP407 previously docked) (Corradi et al., 2006) and 
C-domain (PDB accession code 1O86) were used as molecular templates. Active site ligands 
were modified to the required substrate structure and charge potentials of the new ligand 
fixed. Hydrogen atoms were added to the entire structure, incomplete residues corrected and 
charge of the receptor domain zinc ion was assigned the +2.0 charge. Once the charge 
potentials of the entire assembly were accepted; ligand-receptor energy molecular 
minimisation runs were commenced. The Constant Valence Force Field and Extendable 
Systematic Force Field (metal adapted) were used for minimisation runs. Three thousand 
iterations of molecular minimisation cycles were carried out at 300 K with dielectric constant 
1.00 and cut off distance of 9.5 Å. An average pose of 100 frames was taken as the 
minimised ligand positioning. Interaction distance between the substrate carbonyl oxygen and 
zinc ion, as well as C-terminal interaction with Lys489/511 of the N- or C-domain confirmed 
the reasonableness of the minimised pose. The coordinates of docked substrate poses of the 
N- and C-domains were structurally aligned using ALIGN (Cohen, 1997) and orientations 
compared. 
3.2.5 N-selective fluorogenic substrate: Abz-SDK(Dnp)P 
Fluorogenic substrate Abz-SDK(Dnp)P is an internally quenched peptide that has been 
previously shown to be cleaved 350-fold more efficiently by the N-domain of ACE (Araujo 
et al., 2000). Assays were done in an approach similar to that of section 3.2.3 and, for 
comparison, done under conditions similar to that outlined by (Araujo et al., 2000); with 
variable volumes of a 100 µM Abz-SDK(Dnp)P substrate solution aliquoted into a 96-well 
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plate on ice. Enzyme solution in Tris assay buffer (100 mM Tris-HCl pH 7.0, 50 mM NaCl, 
10 µM ZnCl2) was added to bring the final assay volume to 300 µl and 0.2 (N-domain, 
T496V, R381E, C-domain S2´), 0.8 (YR/FE), 1.2 (Y396F) or 2 (tACE) pmols enzyme. The 
C-domain S2´ protein was kindly made available by Dr W.L. Kröger. This protein contains 
conversion of all unique C-domain S2´ residues into N-domain counterparts and has been 
experimentally assessed to confirm kinetic ability comparable to wild type C-domain (Kroger 
et al., 2009). Baseline fluorescence intensities were measured (λex= 320 nm; λem= 420 nm) 
followed by incubation of the assay at 37°C for 20 minutes (N-domain enzymes and 
C-domain S2´) or 45 minutes (tACE) using a Cary Eclipse spectrofluorimeter (Varian Inc.). 
Samples were reread at the above parameters and changes in intensities compared to baseline 
were converted to reaction velocities by use of the standard curve (Appendix A4). Kinetic 
constants Km and kcat were determined by nonlinear regression analysis (v 4.01, GraphPad 
Prism
®
). 
3.2.6 Physiological substrate: AcSDKP 
3.2.6.1 The development of a novel AcSDKP assay using fluorescamine 
An adapted plate assay was designed based on previously published approach for N-acetyl-
AngI (Conroy and Lai, 1978) using fluorescamine (4-phenylspiro[furan-2(3H),1´-phthalan]-
3,3´-dione), a reagent that forms fluorescent adducts exclusively with primary amines 
(Udenfriend et al., 1972). In order to clarify the effect of enzyme and substrate on basal 
fluorescence, the following conditions were set up: 15 nmols of AcSDKP and 0.3 pmols of 
N-domain were separately aliquoted into triplicate wells of a 96-well plate to a final volume 
of 40 µl. Additionally; enzyme and substrate were incubated together to note the change 
compared to basal fluorescence. Plates were incubated at 37°C for 15 minutes and stopped by 
the addition of 50 µl 1 M HCl. The solution was neutralised by the addition of 50 µl 
1 M NaOH and the pH increased to 8.3 by the addition of 100 µl 500 mM K2HPO4/KH2PO4 
buffer pH 8.3. Ten microlitres of fluorescamine (2 mg/ml in acetone, Sigma-Aldrich Co.) was 
added and the resulting mixture incubated for 3 minutes at room temperature. Fluorescence 
intensities were measured at λex= 390 nm and λem= 475 nm using a Cary Eclipse 
spectrofluorimeter (Varian Inc.). 
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3.2.6.2 Construction of Lys-Pro standard curve 
A range of AcSDKP (0 to 30 nmols) was incubated in HEPES buffer (50 mM HEPES, 
pH 7.5, 100 mM NaCl, 10 µM ZnSO4) with 2 pmol N-domain enzyme at 37°C overnight. 
Thirty microlitre aliquots were transferred into a 96-well plate followed by addition of 10 µl 
assay buffer. The addition of HCl, NaOH, buffer, fluorescamine and measurement of 
fluorescence intensities was measured as above (section 3.2.6.1).  Fluorescence intensities 
were subtracted from 0 nmol baseline readings and a subsequent curve was constructed 
correlating change in fluorescence with product amount (Appendix A4). 
3.2.6.3 Determination of kinetic parameters 
Thirty microlitres of AcSDKP substrate in HEPES buffer, ranging in concentration from 0 to 
1000 µM, were warmed to 37°C in a 96-well plate. The assay was commenced by the 
addition of 10 µl pre-warmed enzyme (0.2 pmols in HEPES buffer) and incubated for 
15 minutes for N-domain and sACE and 30 minutes for the C-domain. The assay was 
stopped, neutralised, buffered, derivitised and read as above (section 3.2.5.1). Changes in 
fluorescence compared to unhydrolysed substrate were converted to reaction velocities by the 
use of a standard curve (as constructed in section 3.2.6.2) and kinetic constants calculated 
from nonlinear regression analysis (v 4.01, GraphPad Prism
®
).   
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3.3 Results 
3.3.1 Inner filter effect correction values  
Increasing substrate concentrations in the presence of a fixed concentration of free donor 
(Abz-Gly) caused a non-linear decrease in measured fluorescence intensities. Correction 
values were calculated as described in section 3.2.2.2.2. The fitting and determination of a 
polynomial derived trend line and equation allowed for the correction of quenching substrate 
concentrations ranging from 0 to 50 µM (Figure 3.2). 
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Figure 3.2: Graph of correction value versus increasing intact substrate Abz-SDK(Dnp)P with 
0.5 µM Abz-Gly. Ratios of changes in fluorescence compared to a zero substrate control 
(containing 0.5 µM Abz-Gly alone) were calculated and plotted. A quadratic equation was 
fitted that best described the data obtained and the equation was subsequently used for 
correction of kinetic experiments with substrates containing Abz and Dnp moieties. Data 
represented as mean ± SEM.   
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3.3.2 Non-selective fluorogenic substrate: Abz-FRK(Dnp)P 
Initial kinetic assessment was performed in order to confirm catalytic integrity of enzymes 
containing active site mutations. Non-selective fluorogenic substrate Abz-FRK(Dnp)P had 
similar binding affinities between the two wild type domains and a slightly higher turnover 
rate for the C-domain, consistent with the original publication (Table 3.1) (Araujo et al., 
2000). Overall catalytic efficiencies for N-domain mutant derivatives were found to be within 
range of controls with the exception of ST/VV which displayed a 10-fold lower catalytic 
efficiency compared to the N-domain.   
 
Table 3.1: Binding affinity (Km), turnover rates (kcat) and catalytic efficiencies (kcat/ Km) of 
C-domain, N-domain and selected N-domain mutant enzymes in the processing of substrate 
Abz-FRK(Dnp)P.  
Enzyme kcat (s
-1
) Km (µM) kcat/Km (s
-1
.µM
-1
) 
N-domain 1.51 10.23 0.148 
C-domain 8.72 11.91 0.732 
Y369F 1.31 10.99 0.119 
R381E 8.47 27.66 0.306 
YR/FE 12.8 13.51 0.947 
T496V 1.47 3.808 0.386 
E262S 2.40 10.35 0.232 
D354E 1.04 4.146 0.251 
S357V 0.892 12.24 0.0729 
T358V 3.54 13.41 0.264 
ST/VV 0.196 15.21 0.0129 
E431D 0.830 4.674 0.178 
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3.3.3 Synthetic substrates: Z-FHL and HHL 
3.3.3.1 Z-FHL/HHL ratios 
Z-FHL/HHL ratios of rates of hydrolysis for the N-domain were approximately 11-fold 
greater than those for the C-domain (Figure 3.3). Comparison of relative rates of hydrolysis 
for both substrates indicated that conversion of N-domain residues to their corresponding 
C-domain counterparts resulted in a change in ratio. Most mutations in both the S2 and S2´ 
subsites resulted in a decrease toward a more C-domain-like ratio (Figure 3.3). The mutants 
Y369F (together with its double mutant YR/FE) and double S2´ mutant ST/VV caused the 
greatest decrease in ratio. 
 
 
Figure 3.3: Ratios of rates of hydrolysis of substrates Z-FHL and HHL by different N-domain 
mutants. Hydrolysis rates of each enzyme toward substrates Z-FHL and HHL were 
determined as described in section 3.2.4.2 and ratios calculated. Wild type N-domain and 
C-domain are shown in dark grey, N-domain active site mutants are shown in light grey and 
the subsite location of residues also indicated. Data represented as mean ± SD. 
 
3.3.3.2 Determination of kinetic parameters 
The active site mutants displaying the greatest change in ratio in each subsite (Y369F and 
ST/VV) were further analysed for their kinetic capabilities toward substrates Z-FHL and 
HHL. N-domain enzymes analysed processed Z-FHL with superior binding affinity and 
turnover rate compared to HHL (Table 3.2). The C-domain displayed considerably better 
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catalytic efficiencies for both substrates. Ratios of turnover rates between substrates were 
approximately equal to the ratios of rates of hydrolysis by the enzymes presented above 
(section 3.3.3.1). 
When compared to wild type, N-domain active site mutant Y369F showed similar turnover 
rates of Z-FHL, and markedly improved catalysis of substrate HHL. N-domain mutant 
ST/VV, as with Abz-FRK(Dnp)P, displayed substantial decreases in kcat values for both 
substrates compared to wild type N-domain. These N-domain mutants that display similar 
ratios to the C-domain did not display similar kinetic abilities, as is evinced by noticeably 
lower kcat values when compared to wild type C-domain (Table 3.2).  
 
Table 3.2: Binding affinity (Km), turnover rates (kcat) and catalytic efficiencies (kcat/ Km) of 
C-domain, N-domain and selected N-domain mutants (Y369F and ST/VV) with substrates 
Z-FHL and HHL. Data given as mean ± SEM. 
Enzyme Substrate kcat (s
-1
) Km (mM) kcat/Km (s
-1
.mM
-1
) 
N-domain 
Z-FHL 48.7 ± 3.55 0.78 ± 0.023 62.2 ± 2.79 
HHL 7.57 ± 0.37 1.31 ± 0.04 5.76 ± 0.20 
Y369F 
Z-FHL 42.8 ± 0.77 0.467 ± 0.012 91.65 ± 1.10 
HHL 26.5 ± 1.62 1.754 ± 0.13 15.13 ± 0.32 
ST/VV 
Z-FHL 7.36 ± 0.40 0.446 ± 0.0128 16.5 ± 0.89 
HHL 2.94 ± 0.11 1.250 ± 0.1021 2.37 ± 0.126 
C-domain 
Z-FHL 99.96 ± 3.74 0.071 ± 0.014 1495.6 ± 214.7 
HHL 107.5 ± 6.44 0.780 ± 0.04 137.7 ± 5.2 
 
3.3.3.3 Molecular modelling of Z-FHL and HHL substrates 
To investigate the interactions between N-domain active site residues and substrates Z-FHL 
and HHL, molecular docking was performed and substrates successfully minimised in both 
domains. Interaction distances between the scissile carbonyl group of the substrates and the 
catalytic zinc ion, as well as bonding distances between substrate C-termini and the 
conserved Lys489/511 residues were noted (Figure 3.4). A change in HHL substrate 
orientation appears to occur with the benzoyl moiety in the N-domain active site possibly due 
to the presence of the terminal hydroxyl group of Tyr369 and residue Arg381. Substrate 
Z-FHL seemed to appear more constrained in the apparently smaller N-domain S2 subsite 
than the C-domain counterpart. For both substrates the P2´ Leu was orientated in the opposite 
direction compared to the C-domain.   
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Figure 3.4: Molecular minimisations of synthetic substrates HHL (A) and Z-FHL (B) in the 
N- and C-domains. Minimisations were performed as outlined in section 3.2.4.4 and domains 
superimposed using the ALIGN program (Cohen, 1997). N- and C-domain substrates, 
residues and zinc ions are shown in green and blue respectively. Interaction distances 
between the catalytic zinc and conserved lysine residues were noticed for all models. Two 
major changes in substrate orientation for HHL between domains were noticed; namely the 
hippuryl group and the P2´ leucine. Image generated using PyMOL software (v 0.99, DeLano 
Scientific).   
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3.3.4 N-selective fluorogenic substrate: Abz-SDK(Dnp)P 
Assessment of contribution of the S2 and S2´ subsites in N-selective substrate processing was 
performed with substrate Abz-SDK(Dnp)P. Catalytic efficiencies of Abz-SDK(Dnp)P 
binding and hydrolysis were determined for N- and C-domain enzymes and revealed 28-fold 
more efficient processing by the N-domain (Table 3.3). N-domain enzymes with mutations in 
the S2 subsite were analysed under the same kinetic conditions. The S2/S1 mutant T496V 
showed a catalytic efficiency comparable to that of wild-type N-domain; while N-domain S2 
mutants (Y369F, R381E and YR/FE) showed more notable changes in catalytic efficiencies. 
Mutants containing the R381E mutation (R381E and YR/FE) displayed a large increase in Km 
values resulting in lowered overall catalytic efficiencies. The single Y369F mutation showed 
the greatest alteration in catalytic efficiency, with a 5-fold lower kcat/Km than wild-type 
N-domain. Interestingly, a C-domain enzyme containing mutations of all unique amino acids 
in the S2´ subsite into their corresponding N-domain counterparts showed marked 
improvement in catalytic efficiency (Figure 3.5).  
 
Table 3.3: Binding affinities (Km), turnover rates (kcat) and overall catalytic efficiencies 
(kcat/Km) for N-domain, C-domain and subsite mutant enzymes in Abz-SDK(Dnp)P 
processing. All data represented as mean ± SD.  
Enzyme kcat (s
-1
) Km (µM) kcat/Km (s
-1
/ µM
-1
) 
N-domain 7.41 ± 0.00707 50.6 ± 1.47 0.146 ± 0.00424 
Y369F 3.43 ± 0.0523 108 ± 35.4 0.0326 ± 0.0058 
R381E 14.1 ± 1.09 265 ± 16.1 0.0529 ± 0.000919 
YR/FE 10.8 ± 1.81 254 ± 57.5 0.0428 ± 0.00255 
T496V 7.48 ± 0.233 41.2 ± 3.04 0.181 ± 0.00778 
C-domain S2´ 7.99 ± 1.08 192 ± 9.76 0.0416 ± 0.00354 
C-domain 0.35 ± 0.028 69.0 ± 9.81 0.00512 ± 0.000276 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 
66 
 
N
-d
om
ai
n
Y
36
9F
R
38
1E
Y
R
/F
E
T
49
6V
'
2
C
-d
om
ai
n 
S
C
-d
om
ai
n
0.00
0.05
0.10
0.15
0.20
k
c
a
t/
K
m
 (
s-
1
. 
M
-1
)
 
Figure 3.5: Overall catalytic efficiencies (kcat/Km) of N-domain, C-domain and mutant 
enzymes in the processing of Abz-SDK(Dnp)P. Enzymatic efficiencies of Abz-SDK(Dnp)P 
cleavage were determined as outlined in section 3.2.4. Wild type and mutant enzymes are 
coloured in dark and light grey respectively. Data represented as mean ± SD. 
 
3.3.5 Physiological substrate: AcSDKP 
3.3.5.1 Assay development 
In order for fluorescamine to be successfully utilised to determine ACE activity, several basic 
assay requirements needed to be clarified; namely the effect of enzyme on basal fluorescence, 
the extent of basal substrate derivitization (since AcSDKP has a free amine on the P1´ Lys in 
the unhydrolysed form); and the need for a reproducibly significant difference between 
substrate and product fluorescence after derivitisation. 
A 5-fold higher amount of enzyme than normally used in standard enzymatic assays (1 pmol) 
had no difference in fluorescence compared to buffer alone. Also, addition of the same 
amount of enzyme after the assay was stopped added no additional fluorescence (Figure 3.6). 
N-domain activity shows a clearly distinguishable difference between product and 
unhydrolysed substrate. Further, as can be noted in the Lys-Pro standard curve, there was 
linearity within the range of detection for this study (Appendix A4). Such observations 
suggested the applicability of the technique in the assessment of ACE activity toward the N-
selective substrate and the approach was employed in subsequent AcSDKP experiments.  
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Figure 3.6: Assay development for the use of fluorescamine in the kinetic assessment of 
AcSDKP hydrolysis. Buffer in the presence of 375 µM AcSDKP ([S]+buffer), 1 pmol 
N-domain enzyme (buffer+[E]) or substrate and enzyme after the addition of HCl (BZT) 
were derivitised with fluorescamine and fluorescence intensities determined. Substrate and 
enzyme co-incubated for 15 minutes ([S]+[E] assay) displayed a marked changed in 
fluorescence intensity compared to the equivalent of uncleaved substrate, suggesting a 
usefulness of the assay approach. All data represented as mean ± SEM.  
 
3.3.5.2 Determination of kinetic parameters 
Assessment of the binding and hydrolysis of physiological substrate AcSDKP was performed 
using an assay approach with fluorescamine, a derivitising agent that results in fluorescent 
signal when derivitised to primary amines. Soluble N-domain analysis with this approach 
indicated a similar turnover rate compared to the sACE with inactivated C-domain 
(Table 3.4) (Rousseau et al., 1995). A slightly higher Km than previously reported above was 
noted; but a higher Km for soluble N-domain (compared to sACE) is consistent with another 
report in the literature publishing the kinetic parameters of ileal (soluble N-domain) ACE 
using an HPLC-based assay (Deddish et al., 1996). 
Km values were similar for all enzymes tested, consistent with other reports (Rousseau et al., 
1995; Deddish et al., 1996). While the N-domain had a similar turnover rate to that 
previously published, the C-domain displayed remarkably higher turnover rate (Table 3.4). 
Wild-type sACE, with both domains active, displayed the highest kcat value. Comparison of 
catalytic efficiencies indicated two important observations. Firstly, the N-specificity of the 
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soluble domains was only 2-fold and, secondly; that soluble domains are additive for the 
overall catalytic efficiency of sACE (Figure 3.7).     
Table 3.4: Binding affinities (Km), turnover rates (kcat) and overall catalytic efficiencies 
(kcat/Km) for N-domain, C-domain and sACE in AcSDKP processing. Data represented as 
mean ± SEM. 
Enzyme kcat (s
-1
) Km (µM) kcat/Km (s
-1
.µM
-1
) 
N-domain 14.2 ± 1.15 240.5 ± 30.75 0.0601 ± 0.004798 
C-domain 4.75 ± 0.68 166.6 ± 29.95 0.0287 ± 0.0011 
sACE 25.4 ± 0.721 288.5 ± 35.40 0.0903 ± 0.00984 
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Figure 3.7: Overall catalytic efficiencies (kcat/Km) of N-domain, C-domain and sACE 
enzymes in the processing of AcSDKP. Enzymatic efficiencies of AcSDKP cleavage were 
determined as outlined in section 3.2.6.3. Data represented as mean ± SEM.  
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3.4 Discussion 
Initial assessment of catalytic ability was performed using fluorogenic substrate 
Abz-FRK(Dnp)P (Araujo et al., 2000). Since it is moderately non-specific for the ACE 
domains, one could anticipate that conversion of N-domain residues into corresponding 
C-domain counterparts should not drastically affect kinetic ability of mutant enzymes and 
that the catalytic efficiencies of these mutants should fall within the range of wild type 
controls. This analysis confirms the catalytic integrity of such N-domain active site mutants.  
A minor increased catalytic ability of the C-domain was observed and is consistent with 
another literature report (Araujo et al., 2000). Mutant enzymes displayed catalytic 
efficiencies that were comparable to the N-domain wild-type control, or alternatively, within 
the range between N- and C-domain controls. The notable exception was that of double S2´ 
mutant; ST/VV, which displayed a similar binding affinity for the substrate as wild-type but a 
10-fold reduction in turnover rate. This suggests that these two residues are not necessarily 
directly involved in substrate binding but their conversion could affect the stabilisation of the 
tetrahedral intermediate (Fernandez et al., 2001; Sturrock et al., 2004). It is thus suggested 
that the introduction of hydrophobic valines into an otherwise N-domain pocket (containing 
other unconserved amino acids) causes changes in subsite architecture (see discussion below 
regarding molecular minimisations of synthetic substrates).     
Previous publications by Danilov and co-workers outlined the usefulness of Z-FHL/HHL 
ratios in assessing the presence of ACE inhibitors in blood and the status of sACE under 
certain denaturing conditions; and showed an increased N-domain ratio compared to 
C-domain (Williams et al., 1996; Danilov et al., 2008). We thus hypothesised that conversion 
of N-domain residues to C-domain counterparts would tend to cause a decrease in ratio. This 
trend was noticed, with the majority of mutants displaying decreased ratios. The removal of 
the tyrosine hydroxyl group and a more hydrophobic S2´ subsite resulted in a ratio close to 
that of the C-domain, suggesting the important roles of these residues in specific substrate 
processing. However, ratios do not make it clear as to the exact kinetic nature of the mutant 
active site in the binding and hydrolysis of HHL and Z-FHL. More extensive kinetic analysis 
was required to assess whether such mutations improve overall catalytic abilities in respect of 
the substrates Z-FHL and HHL.  
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Wild-type N-domain and mutant Y369F showed similar turnover rates of Z-FHL, while 
improved HHL catalysis by Y369F suggests the importance of the terminal hydroxyl group 
of tyrosine in minimising HHL catalysis by the N-domain.  
The double S2´ mutant ST/VV, despite having a ratio similar to the C-domain, does not in any 
way resemble the catalytic efficiency of the C-domain. This emphasises the limitations of the 
above ratios, whereby a decrease in ratio does not necessarily indicate a more 
―C-domain-like‖ molecule in the binding and hydrolysis of substrates. Indeed, neither Y369F 
nor ST/VV display comparable kinetics to the C-domain as could be inferred by the 
Z-FHL/HHL ratios. This study suggests that, while the ratios may be useful for certain 
applications, more subtle active site amino acid changes can be misleading in modifications 
of the Z-FHL/HHL ratio. 
Molecular models of Z-FHL and HHL in the domain active sites are in agreement with the 
above kinetic findings and provide a possible structural perspective of substrate cleavage 
(Figure 3.4). The benzoyl moiety of HHL is found to be in a different orientation in the 
N-domain, possibly due to a steric clash with the Tyr369 terminal hydroxyl group. Due to 
similar binding affinities of HHL between domains it could be suggested that removal of the 
hydroxyl group allows for the substrate in the C-domain to more readily assume the required 
positioning in order to be cleaved (that is, to form the tetrahedral intermediate). The presence 
of a more hydrophilic (due to the presence of Ser357 and Thr358 as opposed to hydrophobic 
valines) and spatially smaller S2´ subsite could account for the changes in orientation of the 
P2´ Leu between the two active sites (Corradi et al., 2006).  
The ST/VV mutant, consistent with the Abz-FRK(Dnp)P kinetics (Table 3.1), is very poor in 
the cleavage of both synthetic substrates. A possible explanation of this reduced catalysis is 
that the introduction of bulkier hydrophobic residues into an otherwise N-domain pocket 
could cause a change in S2´ subsite architecture different to that observed in crystal 
structures. This could result in decreased contacts with Gln259, Lys489 and Tyr498, residues 
considered critical in the stabilisation of the substrate molecule during cleavage, and 
therefore decreased catalytic ability (Matthews, 1988; Sturrock et al., 2004). Another ACE 
mutagenic study supports the above suggestion: conversion of C-domain residue Tyr200 to 
Phe resulted in a 15-fold reduction in turnover rate with substrate furanacrylolyl-Phe-Gly-Gly 
and had little effect on substrate binding but a 100-fold decrease in lisinopril binding affinity, 
suggesting a role of the Tyr residue in contributing to the stabilisation of the tetrahedral 
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intermediate (Chen et al., 1992). Crystal structures show that this residue is distant to bound 
ligands (greater than 10 Å) and thus, like ST/VV, suggests an indirect role in affecting 
stabilisation of the tetrahedral intermediate.  
Z-FHL has the appearance of being more spatially constrained in the N-domain and this work 
could provide a structural basis for the observation of Z-FHL having improved binding 
affinity and turnover rates for the C-domain. Again, this could be attributed to the C-domain 
residues enabling easier positioning of the substrate for hydrolysis (Corradi et al., 2006).  
The fluorogenic substrate Abz-SDK(Dnp)P had originally been reported to have an 
N-domain selectivity of more than 300-fold due to the C-domain being very slow in the 
cleavage of the substrate (Araujo et al., 2000).  The present study was unable to reproduce 
such a large degree of selectivity, with a 28-fold N-selectivity noted. Lower than reported 
selectivity was observed despite the assay being attempted at different temperatures and 
buffer conditions (data not shown). Differences between enzyme derivatives employed 
(truncated, individual domains in this study versus full length sACE, domain inactivated 
enzymes) could be suggested to contribute to the decreased selectivity. Indeed, a 20-fold 
lower selectivity was also noted in the physiologically relevant substrate AcSDKP using the 
same truncated enzymes with a completely different assay (section 3.3.4.2). Nonetheless, 
Abz-SDK(Dnp)P under these conditions can still be considered as a substrate specific for the 
N-domain and relevant mutations were characterised for their effect on Abz-SDK(Dnp)P 
binding and turnover.  
Implications in the literature of the prominent involvement of the S2 subsite (see Chapter 1) 
prompted this study to investigate the effects of mutations in this subsite on Abz-SDK(Dnp)P 
kinetics. Conversions in the N-domain S2 subsite (Y369F, R381E and YR/FE) resulted in 
three to five fold decreases in catalytic efficiencies of the fluorogenic substrate, while 
S2/S1 subsite border mutant derivative T496V had no effect on Abz-SDK(Dnp)P catalysis. 
This kinetic analysis suggests a modest role of several distinct residues within the S2 subsite 
in contributing to the overall selective processing of this substrate and further implies the 
contribution of several other residues working in concert towards N-selective substrate 
processing. This study is in agreement with other studies implicating the substrate P2 group in 
selective processing of Abz-SDK(Dnp)P derivatives (Michaud et al., 1999; Araujo et al., 
2000). While other unique N-domain residues are present in the S1 subsite (Ser119, Asn494), 
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these appear distal from any ligands in the crystal structures available and suggests lack of 
significant contributions to substrate and inhibitor binding.  
In order to compare the role of the S2 subsite with that of the S2´ subsite in the N-selectivity 
of Abz-SDK(Dnp)P, a C-domain enzyme containing all unique S2´ residues converted to their 
N-domain counterparts was kinetically assessed. Such a mutant was utilised due to the 
seemingly poor kinetics of N-domain mutant ST/VV; which would provide misleading 
results due to poor overall general cleavage. Unexpectedly; a 10-fold increase in C-domain 
S2´ mutant enzymatic efficiency compared to wild type C-domain was noted. This was 
surprising since the above reports suggest that the determinants for N-selective substrate 
processing lie within the abovementioned unprimed subsites. These kinetic data suggest that, 
while residues in the S2 subsite of the N-domain do indeed play a contributing role to 
selectivity, the determinants for overall Abz-SDK(Dnp)P selectivity involves interplay 
between a number of enzyme subsites. Such interplay between subsites in contributing to 
ACE selectivity has been noted in the binding of phosphinic inhibitor RXPA380 (Kroger et 
al., 2009) and will be the focus of future investigation.  
In general, mutations in the S2 and S2´ subsites of the N-domain active site have revealed 
some important amino acids contributors in substrate processing. ST/VV was a poor enzyme 
for Abz-FRK(Dnp)P, Z-FHL as well as HHL and, while binding affinity for the substrate was 
comparable to wild type for the substrates tested, the turnover rates were very much lower. 
Structural suggestions of this phenomenon have been presented above. Y369F, while having 
a comparable catalytic efficiency with Abz-FRK(Dnp)P to wild type, had improved HHL 
catalysis and decreased catalysis of N-specific substrate Abz-SDK(Dnp)P and suggests a 
consistent role of this residue in the specific substrate processing of the N-domain. 
Previous work involving AcSDKP kinetics involved the use of paper chromatography or 
HPLC, neither of which allow for high throughput kinetic characterisation (Rousseau et al., 
1995; Deddish et al., 1996; Michaud et al., 1997).  Since AcSDKP has an acetylated, and 
therefore protected, N-terminus it has been identified as a possibly useful substrate for such 
high throughput analysis using an appropriate derivitising agent. 
Fluorescamine is a reagent that forms adducts exclusively with primary amines. Although 
fluorescamine itself is not fluorescent; derivitisation to primary amines forms fluorescent 
adducts resulting in a detectable fluorescence signal (Udenfriend et al., 1972). Due to the 
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introduction of a new peptide N-terminus by hydrolysis of an amide bond, fluorescamine has 
been used to monitor ACE activity in the cleavage of N-acetyl-AngI and substance P (Conroy 
and Lai, 1978; Yokosawa et al., 1983), as well as other enzymes (Wang et al., 2001; Kang et 
al., 2002). Precedent in the literature therefore suggests a plate adaptation assay of 
fluorescamine could be used to monitor the conversion of AcSDKP into inactive products. 
Basal fluorescence of enzyme and uncleaved substrate was low and N-domain enzyme 
activity resulted in a large change in fluorescence compared to substrate alone. The negligible 
effect of enzyme on fluoresence is to be expected due to the amount of enzyme present being 
below the sensitivity of the derivitising agent (Udenfriend et al., 1972). The assay thus 
appeared feasible to be employed in the analysis of AcSDKP kinetics. 
Comparison of wild type soluble human N-domain to the human sACE N-domain active 
form shows a similar turnover rate (Rousseau et al., 1995). The Km values are higher than 
Rousseau et al. (1995), in agreement with previous work that assessed the soluble ACE 
domains in ileal ACE (N-domain) and rabbit tACE (C-domain) using HPLC and also showed 
decreases in substrate binding affinities (Deddish et al., 1996). The selectivity of AcSDKP 
for the domains is markedly reduced with N-selectivity being only 2-fold. Deddish et al. 
(1996) found a similar decrease in selectivity; with AcSDKP having approximately 8-fold 
N-selectivity. In this study, while the N-domain had a turnover rate similar to a previous 
report, the C-domain had a considerably higher turnover rate thus decreasing the overall 
selectivity.  Increased C-domain activity could be due to the assay conditions. In the original 
publication of the N-selectivity of AcSDKP processing (Rousseau et al., 1995); salt 
concentration of 50 mM NaCl was used in the prepared assay buffers despite showing that 
close to maximal activity of both domains was at a more physiological concentration of 
100 mM NaCl. This study sought to mimic the physiological context and therefore utilised 
conditions of 100 mM NaCl as was the case with other authors (Deddish et al., 1996). Thus, a 
contributor to higher C-domain activity in this study is probably due to the use of an optimal 
chloride concentration for the C-domain. 
Domain cooperativity has been observed whereby the overall activity of sACE empirically 
equates to the mean activity of the two separate domains, suggesting that the domains do not 
function in an independent manner. Both human and bovine ACE displayed such functional 
behaviour with synthetic tripeptides (Binevski et al., 2003; Skirgello et al., 2005; Woodman 
et al., 2005). Further work with physiological substrates and human ACE enzymes showed a 
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similar result for AngI and Ang(1-7), but not Ang(1-9) suggesting that this cooperativity is 
not the case for every ACE substrate (Rice et al., 2004). The current study shows that the 
overall efficiency of sACE in AcSDKP processing is not the mean of the individual N- and 
C-domains but additive of the respective individual domain efficiencies. Under these 
conditions, it appears that both domains have the ability to be efficient in the cleavage of 
AcSDKP. However, numerous other publications support the predominant role of the 
N-domain in AcSDKP cleavage in vivo (Azizi et al., 1996; Junot et al., 2001; Fuchs et al., 
2004; Li et al., 2010). Further work is required in order to assess the exact molecular basis of 
this reduced selectivity and additive effect. This study found decreases in both 
Abz-SDK(Dnp)P and AcSDKP selectivities. The previously established substrate selectivities 
were performed using the sACE domain inactivated forms of the enzyme (Rousseau et al., 
1995; Araujo et al., 2000), and this work suggests that the individual domains do have 
different kinetic behaviour that warrants further investigation. The resolution of a sACE 
crystal structure could assist in providing a structural perspective and the relative domain 
orientation in sACE substrate and inhibitor binding.  
A novel plate adapted assay has been designed and shows promise for the use in studies 
which require a more high-through put approach in the assessment of AcSDKP. Such an 
assay approach could be important for the testing of a number N-selective inhibitors and their 
effect on in vitro AcSDKP processing. 
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Chapter 4 
Mutational effects on RXP407 binding and the design of novel N-selective 
inhibitors 
 
4.1 Introduction 
ACE inhibitors have been effectively employed in a wide variety of clinical settings ranging 
from the management of hypertension to diabetic nephropathy; highlighting the central role 
of ACE in pathologies relating to vascular function. Whilst ACE inhibitors are very often an 
efficacious form of treatment, ADEs can cause discomfort to patients and lead to the 
discontinuation of treatment in more severe cases (Speirs et al., 1998; Morimoto et al., 2004). 
Further work has implicated that BK buildup associated with dual blockade of ACE could be 
a major contributor to the occurrence of ADEs (Nussberger et al., 1998; Emanueli et al., 
1998). This, coupled with the finding of two similar yet distinct functioning ACE domains 
(Wei et al., 1991; Fuchs et al., 2004; Fuchs et al., 2008), has lead to the hypothesis that 
selective inhibition of one particular domain could still maintain efficacy whilst leaving the 
second domain free in the degradation of BK (Acharya et al., 2003; Ehlers, 2006).  
The N-domain is the principle enzyme for the degradation of haemoregulatory and 
anti-fibrotic agent AcSDKP and build up of this peptide has been shown to lower collagen 
deposition in a variety of tissues (reviewed in Chapter 1). Further, elevation of AcSDKP 
plasma levels through N-domain inactivation reduces pulmonary fibrosis associated with 
bleomycin administration (Li et al., 2010). Thus, selective N-domain inhibition could be 
utilised in co-administration with chemotherapeutic bleomycin and as a possible treatment for 
pulmonary fibrosis of which there are currently no approved drugs (du Bois, 2010).   
The phosphinic peptidomimetic inhibitor RXP407 is the only inhibitor developed that 
displays marked N-selectivity of three orders of magnitude (Table 4.1) (Dive et al., 1999). 
The synthesis of RXP407 analogues led to the identification of the P2 Asp and N-acetyl group 
as well as the amidated C-terminus as structural determinants for the selectivity of this 
molecule (Dive et al., 1999). Such findings provide important information regarding the 
subsites involved in N-selective binding (that being the S2 and S2´ subsites) and suggest 
potential unique interactions of residues within those subsites with the inhibitor. Also, the 
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above functionalities can be used in the modification of existing inhibitor templates to 
enhance the N-selectivity of candidates that possess more drug-like characteristics. 
The identification of amino acids that possibly contribute to the selective binding of RXP407 
made use of available structures and docked models (Tzakos and Gerothanassis, 2005; Jullien 
et al., 2006; Corradi et al., 2006; Anthony et al., 2010) and has been reviewed in Chapter 1. 
These residues were converted to their corresponding C-domain counterparts, expressed and 
purified as described in Chapter 2, and their kinetic abilities assessed using the fluorogenic 
substrate (Abz)-FRK(Dnp)P (Chapter 3). Such conversions can shed light on active site 
residue contribution in RXP407 binding and guide the design of N-selective inhibitors. This 
approach has been used to successfully elucidate the molecular basis of RXPA380 
C-selectivity (Kroger et al., 2009).  
Of the clinically used inhibitors, only captopril displays modest selectivity for the N-domain 
active site (Wei et al., 1992). While several established ACE inhibitors can potently inhibit 
ACE activity, only captopril was able to differentiate between AcSDKP and AngI hydrolysis 
further supporting its modest N-selectivity described above (Michaud et al., 1997). Since the 
C-terminal amide is crucial for the N-selectivity of RXP407, the simple addition of a 
C-terminal amide could result in a clinically relevant N-selective inhibitor (Table 4.1).  
Keto-ACE (5-S-5-Benzamido-4-oxo-6-phenylhexanoyl-L-proline) is a ketomethylene 
derivative that utilises a carbonyl group for zinc coordination and has been shown to be 
approximately 30-fold C-selective (Table 4.1) (Deddish et al., 1998). The synthetic approach 
for the synthesis of keto-ACE analogues containing different P2 and P2´ functionalities has 
been established previously (Nchinda et al., 2006b) and provides an appropriate starting point 
for the synthesis of additional potentially N-selective inhibitors. These inhibitors thus provide 
templates for the design of novel N-selective inhibitors and modification of these molecules 
to include an N-acetyl group, a P2 Asp and a C-terminal amide could result in more drug-like 
molecules with greatly improved N-selectivity (Table 4.1). 
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Table 4.1: Names, structures and molecular masses of potentially N-selective compounds. 
Compound name Compound structure 
 
Molecular 
mass (g.mol
-1
) 
RXP407 
P
O
OH
N
H
O
NH2
O
N
H
O
N
H
Ph
O
HOOC
 
498.48 
Captopril 
NSH
O
O
OH
 
217.29 
CapNH2 
NSH
O
O
NH2
 
216.30 
Keto-ACE 
NN
H
O
O
O
OPh
OH
 
422.49 
1 
N
H
N
H
O
O
O
Ph
NH2
O
NH
 
510.60 
2 
NN
H
O
O
O
OPh
NH2
 
421.50 
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Table 4.1: continued 
Compound name Compound structure 
 
Molecular 
mass (g.mol
-1
) 
3 
N
H
N
H
O
O
O
Ph
NH2
O
N
N
H
 
461.53 
4 
N
H
N
H
O
O
O
Ph
NH2
O
OH  
411.46 
5 
N
H
N
H
O
O
O
Ph
NH2
O
OH  
487.56 
6 
N
H
N
H
O
O
O
Ph
NH2
O
 
423.52 
7 
NN
H
O
O
OPh
OHO
N
H
O
O
HOOC
 
533.58 
8 
NN
H
O
O
OPh
OHO
N
H
O
HOOC
 
475.50 
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The objectives for the assessment of residue contribution to selective binding and the design 
of N-selective inhibitors were as follows: 
1. To assess the kinetic binding of RXP407 to N-domain active site mutants using the 
fluorogenic substrate Abz-FRK(Dnp)P. 
2. To assess the N-selectivity of a C-terminally amidated captopril analogue, capNH2, 
using the substrate Z-FHL. 
3. To evaluate the N-selectivity of keto-ACE analogues that contain newly introduced 
functionalities in the P2 and P2´ positions; by screening for inhibitory potential and 
subsequent binding characterisation using the substrate Z-FHL. 
4. To perform molecular docking studies of enhanced N-selective molecules positioned 
in the N- and C-domain active sites.  
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4.2 Methods 
4.2.1 Preparation of inhibitors for enzymatic assays 
Phosphinic inhibitor RXP407 was a kind gift from Prof V. Dive (CEA, iBiTecS, Service 
d’Ingénierie Moléculaire des Protéines, France). The solid inhibitor powder was dissolved in 
sterile dH2O and subsequently serially diluted in RXP407 assay buffer (50 mM HEPES 
pH 6.8, containing 200 mM NaCl, 10 μM ZnCl2). ACE inhibitor captopril was purchased 
from Sigma-Aldrich Co. C-terminally amidated captopril (capNH2) was synthesised by Dr S. 
Salisu and keto-ACE analogues with differing P2 and P2´ functionalities synthesised by Dr 
R.K. Sharma (in collaboration with Prof K. Chibale, Department of Chemistry, University of 
Cape Town) (Table 4.1). Captopril and capNH2 were dissolved in sterile dH2O and 
subsequently diluted in phosphate incubation buffer (100 mM KHPO4/KH2PO4 pH 8.3, 
300 mM NaCl, 10 µM ZnSO4, 1 mg/ml albumin). Due to solubility issues, keto-ACE 
analogues were dissolved in 100% DMSO or methanol to yield a 50 mM inhibitor stock 
solution. Aliquots of stock solutions were diluted to 10 mM working stocks with dH2O 
followed by dilution in phosphate incubation buffer.  
4.2.2 Inhibition assays 
4.2.2.1 RXP407 binding constant determination 
Binding affinity of RXP407 was carried out as described previously (Watermeyer et al., 
2008). Briefly, approximately 20 nM enzyme was incubated with an appropriate RXP407 
dilution series in RXP407 assay buffer at room temperature for 90 minutes. Enzyme-inhibitor 
solutions were then aliquoted in triplicate in 20 μl volumes followed by addition of 280 μl 
(Abz)-FRK(Dnp)P (in RXP407 assay buffer) to give a final substrate concentration of either 
4 or 8 μM. Change in fluorescence intensities over time was subsequently monitored using a 
Cary Eclipse spectrofluorimeter (Varian Inc.). Initial velocities were calculated using a 
standard curve correlating moles free Abz produced and fluorescence intensity (Appendix 
A4), and inhibitory binding affinities calculated with a Dixon Plot of inverse reaction velocity 
versus inhibitor concentration (Figure 4.1) (Dixon, 1953). 
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Figure 4.1: A representative Dixon Plot indicating the determination of the Ki value of 
N-domain mutant derivative YR/FE for RXP407. The corresponding x-coordinate of 
intersection of the two straight lines (extrapolated from two different substrate 
concentrations) is indicative of the negative of the Ki value in accordance with (Dixon, 1953). 
Data represented as mean ± SEM. 
 
4.2.2.2 Novel ACE inhibitor analogues 
A dilution series of captopril (0-500 nM) and capNH2 (0-25 µM) in phosphate incubation 
buffer was incubated with N- and C-domains (final concentrations of 2.5 nM and 1 nM 
respectively) for 60 minutes. Triplicate 20 µl aliquots of the enzyme-inhibitor complex were 
aliquoted into a 96-well plate and prewarmed to 37°C. Twenty microlitres of pre-warmed 
substrate (2 mM Z-FHL in phosphate buffer) was added, incubated for 20 minutes shaking 
and subsequent assay steps performed as described previously (section 2.2.5). Percentage 
remaining activity was plotted against inhibitor concentration (in logarithmic scale) and the 
concentration required for 50% enzyme inhibition calculated through the use of a sigmoidal 
dose response curve (GraphPad Prism
®
, v 4.01, see Figure 4.3). 
In order to identify potential N-selective keto-ACE analogues, a broad screen was first 
conducted to identify compounds with minimum threshold of 50% N-domain inhibition at 
250 µM inhibitor concentration. Ten millimolar inhibitor stocks were diluted to 500 µM with 
phosphate incubation buffer, with the exception of compound 1 that required to be assayed at 
a higher concentration because of insolubility at lower concentrations due to a lower DMSO 
concentration. Forty microlitres of inhibitor solution was mixed with 40 µl enzyme (5 nM 
N-domain or 2 nM C-domain) and incubated at room temperature for 90 minutes and assayed 
with Z-FHL as outlined above. Percentage remaining activity was compared to controls 
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containing no inhibitor (with the same organic solvent concentration in phosphate incubation 
buffer). Compounds displaying above threshold inhibition of the N-domain and minimal 
inhibition of the C-domain were further analysed for N-selective inhibition activity.  
Promising inhibitors were further kinetically analysed for their binding affinities toward the 
N- and C-domains. A serial dilution series was incubated with enzyme (as above) in 
phosphate incubation buffer and assayed as above at two substrate concentrations (0.1 mM 
and 1 mM Z-FHL). Inhibition constants (Ki) were calculated using Dixon plots as described 
in section 4.2.2.1. 
4.2.3 Molecular docking of novel keto-ACE analogues 
Ligand docking of N-selective keto-ACE analogues (compounds 7 and 8) into the N-domain 
active site was performed using the computational software platform of Discovery Studio 
(DS, Accelrys Inc., v 2.5). The recently solved RXP407—N-domain co-crystal structure 
(PDB accession code 3NXQ) was used as reference ligand (RXP407) and receptor 
(N-domain) respectively (Anthony et al., 2010). The receptor was prepared by deletion of the 
additional chain as solved in the asymmetric unit cell. Water and non-protein molecules of 
the remaining chain were also deleted. Conformers present in the data file of the N-domain 
were corrected and hydrogen atoms added through the use of the standard ―Clean Protein‖ 
utility within the DS suite. Incomplete residues were corrected and charges of the zinc ion 
and complexing residues assigned. The co-ordinates of the co-crystallised ligand (RXP407) 
were extracted from the receptor and saved separately as a comparative during analysis. The 
spatial arrangement of the reference ligand was used to define a sphere for subsequent 
docking protocols (Figure 4.2). Ligand molecules were drawn using ChemSketch (ACD 
Laboratories, Freeware Edition) and saved in compatible MDL mol format. Drawn structures 
had hydrogen atoms added and the CHARMm forcefield (Brooks et al., 2009) applied to both 
ligand and receptor. Grid docking experiments were performed using the CDOCKER 
protocol (Wu et al., 2003) available on the DS platform with a set output of 10 minimised 
ligand poses. Poses with interaction distance between the zinc ion and carbonyl as well as 
between the C-terminal carboxylate and residues Lys489 and Tyr498 were selected for 
further analysis. Best fit poses were then selected on the basis of the lowest mean energy and 
interaction energy of the selected poses (Wu et al., 2003). The same approach was employed 
with the reference ligand to confirm reasonableness of the docked poses. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4 
83 
 
 
Figure 4.2: Representative figure indicating computationally defined active site sphere of the 
N-domain (PDB accession code 3NXQ) for docking of novel inhibitors. The N-domain 
protein structure is represented as a white-pink ribbon, the catalytic zinc as a grey sphere and 
reference ligand RXP407 shown in stick display. The docking sphere is shown in red and was 
generated by software within DS (Accelrys Inc., v 2.5). Image generated using DS Client 
Visualiser (Accelrys Inc., v 3.0). 
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4.3 Results 
4.3.1 RXP407 binding affinities 
To assess the contribution of N-domain residues towards selective binding of RXP407, 
inhibition binding assays were carried out on N-domain mutant derivatives using 
(Abz)-FRK(Dnp)P as a substrate. As shown previously (Dive et al., 1999), RXP407 showed 
marked N-selectivity with a low nanomolar binding affinity for the N-domain active site and 
micromolar inhibition of the C-domain (Table 4.2). Single amino acid conversions in both the 
N-domain S2 and S2´ subsites displayed modest effects on the selective binding of RXP407 
(Table 4.2). In the S2´ subsite, S357V and E431D showed a three-to-four fold decrease in 
affinity toward RXP407 binding (Ki). Additionally, S2´ mutants E262S, D354E, T358V and 
the double mutation ST/VV showed no effects on inhibitor binding. While S2/S1 subsite 
mutant T496V had no effect on inhibitor affinity compared to wild type control, single 
mutations in the S2 subsite (Y369F and R381E) resulted in modest three-to-six fold lower 
RXP407 binding affinities. Interestingly the double S2 mutant, YR/FE, resulted in a 122-fold 
increase in Ki (Table 4.2) and thus a drastic decrease in inhibitor affinity for the mutant active 
site.  
Table 4.2: Inhibitory binding constants (Ki) of RXP407 to enzyme active sites. Enzyme and 
inhibitor were pre-incubated and activity monitored continuously with substrate 
Abz-FRK(Dnp)P as outlined in section 4.2.2.1. Ki values were calculated by the Dixon Plot. 
Subsite Enzyme Ki (nM) 
- 
N-domain 5.16 
C-domain 2830 
S2 
Y369F 18.0 
R381E 33.5 
YR/FE 631 
T496V 5.99 
S2´ 
E262S 3.66 
D354E 3.52 
S357V 20.5 
T358V 3.40 
ST/VV 3.60 
E431D 17.7 
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4.3.2 C-terminally amidated captopril (capNH2) 
Since C-terminal amidation of RXP407 was previously shown to be important for 
N-selectivity (Dive et al., 1999); captopril, a modestly N-selective and clinically relevant 
drug template was amidated at the C-terminus and assessed for changes in N-selectivity. IC50 
value determination for these two compounds for each domain was employed as an initial 
assessment of the degree of N-selectivity of the captopril analogue capNH2. Captopril 
showed an IC50 value in the low nanomolar range and a selectivity of approximately 3-fold 
for the N-domain, a degree of selectivity consistent with literature reports (Wei et al., 1992; 
Michaud et al., 1997). CapNH2 had an increased IC50 value compared to controls and showed 
an N-selectivity of 6-fold (Figure 4.3). 
 
 
Figure 4.3: IC50 inhibition values for captopril and C-terminally amidated analogue, capNH2. 
Inhibition assays were performed as described in section 4.2.2.2. Captopril displays modest 
3-fold N-selectivity consistent with literature reports while capNH2 shows decreased 
inhibitory potential and 6-fold N-selectivity. Data represented as mean ± SEM.    
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4.3.3 Keto-ACE analogues 
The parent molecule, keto-ACE, has been shown to have binding affinities for both N- and 
C-domains in the lower micromolar range with a C-selectivity of approximately 30-fold 
(Deddish et al., 1998; Nchinda et al., 2006b; Watermeyer et al., 2008). As a control for the 
broad inhibition screen, keto-ACE displayed good inhibition of both domains as evident by 
the low residual enzyme activity at 250 µM inhibitor concentration (Figure 4.4).   
4.3.3.1 Inhibitors containing P2´ functionalities 
Keto-ACE analogues containing various amino acids in the P2´ position, as well as an 
amidated C-terminus, were assessed for inhibitory potential in a broad screen assay 
(compounds 1-6). All amidated keto-ACE analogues showed poor inhibition of the N-domain 
at 250 µM inhibitor concentration (Figure 4.4). Several compounds displayed improved 
inhibition of the C-domain and this inhibitory feature tended to correlate with bulkier and 
more hydrophobic amino acids in the P2´ position. 
4.3.3.2 Inhibitors containing P2 functionalities 
A second group of keto-ACE analogues was generated containing an acidic P2 Asp residue 
and either a t-Boc group or N-acetyl group protecting the N-terminus (compounds 7 and 8). 
These compounds generally showed improved inhibition of the N-domain compared to the 
C-domain at 250 µM (Figure 4.4). In both cases, minimal inhibition of the C-domain was 
noted at this concentration.   
 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4 
87 
 
N-domain
kA 1 2 3 4 5 6 7 8
0
10
20
30
40
50
60
70
80
90
100
110
120
Inhibitors
P
er
ce
n
ta
g
e 
re
m
a
in
in
g
a
ct
iv
it
y
 (
%
)
 
C-domain
kA 1 2 3 4 5 6 7 8
0
10
20
30
40
50
60
70
80
90
100
110
120
Inhibitors
P
er
ce
n
ta
g
e 
re
m
a
in
in
g
a
ct
iv
it
y
 (
%
)
 
Figure 4.4: Inhibition screen of keto-ACE (kA) analogues and their effect on N- and 
C-domain activity. Two hundred and fifty micromolar inhibitor (with the exception of 
compound 1- 2.5 mM) was incubated with 2.5 nM N-domain or 1 nM C-domain and assayed 
as described in section 4.2.2.2. Percentage remaining ACE activity was calculated from a 
zero inhibitor control. Data represented as mean ± SEM. 
 
Ki values of the keto-ACE parent molecule were in the lower micromolar range for both 
domains and displayed 36-fold C-selectivity, consistent with previous reports (Deddish et al., 
1998; Nchinda et al., 2006b; Watermeyer et al., 2008). Inhibitor binding affinities of P2 Asp 
containing compounds 7 and 8 had improved binding affinity for the N-domain displaying 
low micromolar inhibition and an approximately 30-fold selectivity for the N-domain (Table 
4.3). Thus, the addition of an aliphatic N-protecting group and P2 Asp resulted in an increase 
of approximately 1000-fold N-selectivity of these molecules (Table 4.3).  
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Table 4.3: Inhibitory binding constants of keto-ACE and analogues containing P2 Asp 
functionalities. Ki values were determined as in section 4.2.2.2 and N-selectivity calculated as 
the ratio of C-domain Ki over N-domain Ki. Values represented as mean ± SD. 
Compound Structure 
N-domain 
Ki (µM) 
C-domain 
Ki (µM) 
Selectivity 
(C Ki/N Ki) 
keto-ACE NN
H
O
O
O
OPh
OH
 
12.74±0.2333 0.3504±0.0089 0.02750 
7 NN
H
O
O
OPh
OHO
N
H
O
O
HOOC
 
9.790±0.3394 330.0±30.83 33.71 
8 NN
H
O
O
OPh
OHO
N
H
O
HOOC
 
29.11±3.861 913.4±85.23 31.38 
 
4.3.4 Molecular docking of keto-ACE analogues 
Molecular docking of keto-ACE analogues was performed to provide a structural perspective 
of improved N-selective binding. In order to confirm the reliability of the molecular docking 
approach, reference ligands RXP407 and RXPA380 were removed from the predefined active 
sites of the N- and C-domains respectively and re-docked back into their crystal structure 
receptors. Both minimised ligands closely matched the reference poses of the crystal structure 
reference with RXP407 and RXPA380 displaying root mean square deviation (RMSD) 
values of 1.31 Å and 1.73 Å respectively (Figure 4.5). 
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Figure 4.5: Redocked poses of reference ligands compared to the original crystal structure 
coordinates of RXP407 in the N-domain (A) and RXPA380 in the C-domain (B). Molecular 
docking was performed and relevant poses selected as outlined in section 4.2.3. Original 
crystal structure and redocked conformations are shown in line and stick styles respectively. 
In both cases the RMSD value is less than 2.0 Å. Images were generated using DS Client 
Visualiser (Accelrys Inc., v 3.0). 
 
Structures of molecules showing the most prominent N-selectivity of the keto-ACE series 
(compounds 7 and 8) were molecularly docked into the computationally defined active sites 
of the N- and C-domains and appropriate poses selected on predetermined selection criteria. 
Two categories of conformations of molecules in the N-domain were noted for both ligands 
whereby the N-protecting groups displayed two possible positions. For compound 7; the 
t-Boc group either positioned downwards toward the large open active site cleft beyond the 
S2 subsite to allow for the P2 Asp to interact with Tyr369 and Arg381 (Figure 4.6 (A), stick 
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style pose) or the t-Boc itself was able to have interactions with the unique S2 residues and 
the Asp pointed towards the conserved protein backbone (Figure 4.6 (A), line style pose). For 
compound 8; the N-acetyl appears to either position in the open cleft beyond the S2 subsite 
(Figure 4.6 (B), stick pose) or within the S2 subsite (Figure 4.6 (B), line pose). Compound 8 
docks into the N-domain with an apparently conserved P2 Asp interaction with Tyr369 and 
Arg381 between poses.   
 
 
 
Figure 4.6: Two categories of poses obtained from molecular minimisation experiments and 
pose selection analysis of compounds 7 (A) and 8 (B) in the N-domain active site. Molecular 
docking was performed, relevant poses selected as outlined in section 4.2.3 and two 
representative poses indicated in line or stick bond display. In general two categories of poses 
were observed with the varied positioning of the N-protecting group and indicated possible 
hydrogen bonding with unique amino acids in the N-domain. Tyr369, Arg381, Lys489, 
Tyr498 and catalytic zinc ion are included in the diagram. Images were generated using DS 
Client Visualiser (Accelrys Inc., v 3.0). 
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In contrast and as expected, molecular minimisation of ligands in the C-domain active site 
indicated the lack of interactions of compound 7 with amino acids in the S2 subsite due to a 
loss of interaction partners (Tyr369 is replaced by Phe391 and Arg381 is replaced by Glu403 
in the C-domain). Consistent with a model of RXP407 in the C-domain (Tzakos and 
Gerothanassis, 2005), the inhibitor P2 Asp has interactions with Ala356 of the protein 
backbone, which normally the inhibitor backbone carbonyl contacts (Anthony et al., 2010), 
and thus provides a structural visualisation of the basis of the improved N-selectivity of this 
compound (Figure 4.7). No poses of compound 8 in the C-domain met with the 
predetermined selection criteria of this study and were either of wrong orientation or lacked 
appropriate zinc ion coordination suggesting minimal set contacts between inhibitor and 
active site. Such docking corroborates the finding of compound 8 being a very poor inhibitor 
of the C-domain (Ki value close to 1 mM). 
 
 
Figure 4.7: Compound 7 docked into the C-domain active site. The inhibitor P2 Asp and 
t-Boc group lack interactions with unique domain residues, with the Asp seen to interact with 
the protein backbone of C-domain residue Ala356. Zinc ion and amino acids of interest are 
given as shown with hydrogen bonds represented as a broken green line. Image was 
generated using DS Client Visualiser (Accelrys Inc., v 3.0). 
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4.4 Discussion 
Original combinatorial synthesis of RXP407 emphasised the importance of the inhibitor P2 
N-acetyl group and Asp residue, and P2´ C-terminal amide in selective binding of the 
N-domain active site (Dive et al., 1999). Such work thus suggested the importance of 
interactions of unique residues present in the corresponding enzyme subsites and their 
contribution to N-selectivity.   
Numerous single and double mutations in the S2´ subsite of the N-domain resulted in minor 
changes in RXP407 binding affinity, suggesting limited individual roles of these residues in 
N-selective binding. All unique residues within possible binding distance in this subsite have 
been mutated in this study; however, an understanding of the molecular basis of the 
C-terminal amide interaction remains elusive. All computational models (RXP407 docked 
into the N-domain) do not show prominent interaction of the C-terminal amide with unique 
N-domain amino acids (Tzakos and Gerothanassis, 2005; Jullien et al., 2006; Corradi et al., 
2006). In addition, the recently resolved N-domain–RXP407 co-crystal structure indicates 
that the RXP407 C-terminal amide makes contacts with conserved residues Gln259 and 
Tyr498 (Figure 4.8) (Anthony et al., 2010). Although it has been proposed that the amide 
might make a water-mediated hydrogen bond with Thr358 (Anthony et al., 2010), the 
significance of this single interaction as a means to selective binding is not supported by the 
above mutational analysis. With individual interactions in the S2´ subsite apparently not being 
the major player in N-selective binding, it is hypothesised that perhaps the presence of 
several unique residues provide the appropriate environment for C-terminal positioning 
within this subsite. When these residues are removed, as in the C-domain, perhaps subtle 
changes to this environment results in less favourable C-domain binding affinity. Future work 
could involve conversion of all S2´ residues in a single active site to further investigate this 
hypothesis. 
Single mutations of residues in the S2 subsite had little or no effect on RXP407 binding. 
However, conversion of residues Tyr369 and Arg381 in a single active site (YR/FE) resulted 
in a binding affinity of RXP407 more comparable to C-domain binding. This suggests that 
both amino acids make sufficient contact with the inhibitor that, when one residue is 
converted, the other can provide interaction to still allow potent binding. Such information 
provided a useful indication of which molecular models better describe the probable binding 
mode in the N-domain active site (Kroger et al., 2009). The recently solved N-domain–
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RXP407 co-crystal structure supports the above proposal (Anthony et al., 2010). In this 
structure, the P2 Asp of RXP407 is within 3 Å of both Tyr369 and Arg381 thus allowing for 
extensive interaction with both of these residues (Figure 4.8). These findings provide useful 
information for the design of N-selective inhibitors and suggest that future compounds 
contain functionalities that can maximise interactions with Tyr369 and Arg381 in the 
N-domain active site.  
    
 
Figure 4.8: The crystal structure of N-selective ACE inhibitor RXP407 in the N-domain 
(PDB accession code 3NXQ) (Anthony et al., 2010). The RXP407 P2 Asp has prominent 
hydrogen bond interactions with unique N-domain residues Tyr369 and Arg381 while the 
crystal structure indicates nteractions of the P2´ amide only has interactions with domain 
conserved residues Gln259, His491 and Tyr498. N-domain amino acids and inhibitor 
RXP407 are displayed in line and stick style respectively, the zinc ion shown as a sphere and 
hydrogen bonds represented as broken green lines. Image was generated using DS Client 
Visualiser (Accelrys Inc., v 3.0). 
 
A concurrent study was performed to initiate the development of novel N-selective inhibitors. 
With structural determinant investigations of RXP407 revealing the importance of the 
C-terminal amide in the selective binding of this inhibitor (Dive et al., 1999), simple 
modification of existing and potentially clinically relevant ACE inhibitor templates could 
help confer N-selectivity. Captopril, the smallest and most accessible in terms of organic 
synthesis of all the clinical ACE inhibitors, was used as a starting point to investigate this 
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hypothesis. Captopril displays minor N-selectivity, in agreement with previous work (Wei et 
al., 1992; Michaud et al., 1997). While it is difficult to identify the basis of this subtle 
selectivity from the crystal structures available, it has been suggested that energetic 
compensations in the active site could be a determinant (Natesh et al., 2004).  Amidation of 
the C-terminus of captopril, compound capNH2, showed no major change in N-selectivity. A 
possible suggestion is that captopril, being small and largely reliant on the sulphydryl group 
for potency, can position in a slightly different conformation due to its size and lack of other 
interactions. Thus, the possible interactions that the C-terminal amide makes in the S2´ 
subsite of the domains would not be effective in discriminating between domains because 
captopril could adopt a different position due to its size. Indeed, this drug has been shown to 
inhibit several other dissimilar zinc metalloproteases implying the lack of specificity of the 
compound (Thunnissen et al., 2002; Yamamoto et al., 2010). Further work using a keto-ACE 
backbone with compounds containing a C-terminal amide with different P2´ functionalities 
also failed to inhibit the N-domain at 250 µM inhibitor concentration, corroborating the 
mutational analysis with RXP407 above; that mutations in the S2´ subsite have little or no 
effect on inhibitor binding compared to wild type N-domain. Even compound 2, identical to 
the keto-ACE parent molecule with the exception of the C-terminal amide, was a poor 
inhibitor of both domains. Thus, the addition of a C-terminal amide to captopril and keto-
ACE does not increase N-selectivity and appears to reduce inhibitor potency. This decreased 
inhibitory ability suggests that amidation of the C-terminus of these inhibitors renders a less 
effective inhibitory molecule possibly due to reduced interaction with Lys489, an interaction 
considered to be key for ACE inhibitor potency (Natesh et al., 2003; Acharya et al., 2003). 
With this possible loss of interaction, both captopril and keto-ACE do not have additional 
functional groups present elsewhere on the structure to significantly assist in binding. 
RXP407, that appears to lack an interaction with Lys489 in the crystal structure, utilises other 
subsite interactions for ACE binding (particularly the S2 subsite) and thus inhibitory and 
selectivity potential must obviously be optimised in other pockets (Anthony et al., 2010). 
Therefore cooperative binding between the P2 and P2´ groups could possibly play a role, that 
being the C-terminal amide could assist simply in anchoring in a slightly different but unique 
conformation so as to allow for better binding elsewhere in the molecule. Such interplay 
between subsites has been noted for another phosphinic inhibitor, RXPA380 (Kroger et al., 
2009). With this being said, the N-domain co-crystal structure showed no unique interactions 
with the C-terminus, S2´ subsite mutational analysis indicated that mutations had minimal 
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affect on RXP407 binding, and the addition of a C-terminal amide to both captopril and keto-
ACE analogues did not notably increase selectivity. Thus, the role of the C-terminal amide 
remains unclear and future work could involve the addition of a C-terminal amide to P2 Asp 
compounds and subsequent testing on the resultant compound N-selectivity.  
Several compounds containing different P2´ functionalities displayed apparently better 
inhibition of the C-domain (compounds 1, 5 and 6). This observation is consistent with the 
rationale that bulkier, more hydrophobic P2´ functionalities are better accommodated by the 
C-domain S2´ subsite (Georgiadis et al., 2003; Georgiadis et al., 2004; Watermeyer et al., 
2008; Watermeyer et al., 2010) and shows the predominant role of these types of amino acids 
in driving C-selectivity. 
To further investigate the role of inhibitor functional groups in N-selectivity, another 
category of keto-ACE analogues was synthesised containing a free C-terminus and P2 Asp. 
Two molecules, which differed only in the N-protecting group (compound 7 possesses a 
t-Boc while compound 8 contains an acetyl functionality), were able to inhibit the N-domain 
in the low micromolar range and showed moderate (approximately 30-fold) N-selectivity. 
This observation is significant since the parent molecule of keto-ACE is shown to be 
approximately 36-fold C-selective, in agreement with previous studies (Deddish et al., 1998; 
Nchinda et al., 2006b; Watermeyer et al., 2008). Thus, the conversion of a benzoyl group to 
an Asp residue and aliphatic N-protecting group onto the P2 position of keto-ACE contributes 
to a change in selectivity for the N-domain of approximately 1000-fold. 
Docked models of compounds 7 and 8 reveal the potential for the N-protecting group to 
position in two orientations. In the case of compound 7, the carbonyl oxygen of the t-Boc 
group had the possible ability to interact with unique N-domain residue Tyr369. This agrees 
with other studies that suggested that the N-domain could more easily accommodate aliphatic 
moieties than phenyl groups due to the presence of Tyr369 and Arg381, and provides a 
structural perspective as to the reason that keto-ACE analogues containing a P2 t-Boc group 
have improved N-selectivity (Nchinda et al., 2006b; Watermeyer et al., 2008). The N-acetyl 
group of compound 8, being less bulky, could also rotate to fit into the S2 subsite while the P2 
Asp made contacts with active site residues. Such an observation is in agreement with the 
N-domain–RXP407 co-crystal structure where the two solved structures in the asymmetric 
unit had two different positions of the N-acetyl group (Anthony et al., 2010). The P2 Asp in 
both compounds could position to have close contacts with residues Tyr369 and Arg381, in 
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agreement with the crystal structure of RXP407 in the N-domain (Figure 4.8). This 
emphasises the importance of the P2 Asp in providing contacts that can discriminated 
between domains. When Tyr369 and Arg381 are removed, in the case of the C-domain, the 
compounds clearly have minimal contacts with the active site (Figure 4.7). This molecular 
minimisation study provides a structural indication of the importance of inhibitor functional 
group contacts with residues Tyr369 and Arg381 to assist in N-selective binding and aids in 
an understanding as to why such moieties were considered important for RXP407 selectivity 
(Dive et al., 1999). 
The current study emphasises the features critical to improved N-selectivity; namely the 
presence of an N-protecting group and a P2 Asp. Such functional groups appear to make key 
contacts with residues Tyr369 and Arg381 as evinced by crystal structures, N-domain 
mutational analysis and molecular docking minimisation studies. Clearly, maintenance or 
even improvement of these interactions will be required in the next phase of N-selective 
inhibitor development. Also, novel P2 groups that are not naturally occurring amino acids 
could be used to enhance interactions with Tyr369 and Arg381. For example, ketomethylene 
based inhibitors containing oxadiazoyl rings have been successfully used in the development 
of selective inhibition of dipeptidyl peptidase IV possibly due to its interaction with a unique 
Arg residue (Koo et al., 2007).  
In this study, a combined enzyme mutation analysis and inhibitor modification approach has 
allowed for the furthering in understanding of the molecular basis of N-domain inhibitor 
selectivity. This, together with the timely publication of the co-crystal structure of RXP407 in 
the N-domain, contributes to the rational structure-based design of N-selective inhibitors. In 
light of this work, it is suggested that aliphatic groups (and not bulky phenyl moieties) in the 
inhibitor P2 position inhibitors could allow for better accommodation of the inhibitor in the 
N-domain active site, resulting in improved binding potency. Furthermore, future generation 
of N-selective inhibitors should focus to achieve optimal interactions with Tyr369 and 
Arg381. Such prominent interactions should allow for discrimination between active sites, as 
is noticed when these two residues are mutated and subsequent binding of RXP407 is more 
than 100-fold reduced. These future inhibitors have exciting potential application in treatment 
of various tissue fibrosis conditions due to the potent anti-fibrotic effect of AcSDKP buildup 
(Cavasin, 2006; Cavasin et al., 2007; Li et al., 2010).  
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Chapter 5 
Conclusions and Future Directions 
 
This study sought to determine the extent of unique N-domain active site residues in 
contributing towards N-selective inhibitor binding and substrate processing. The S2 and S2´ 
subsites were implicated as important for N-selectivity through the previous generation of 
substrate and inhibitor analogues (Michaud et al., 1997; Michaud et al., 1999; Dive et al., 
1999; Araujo et al., 2000), and important residues within these subsites identified through the 
use of available molecular models and crystal structures (Tzakos and Gerothanassis, 2005; 
Jullien et al., 2006; Corradi et al., 2006; Akif et al., 2010a; Anthony et al., 2010). Amino 
acids of interest were converted to their corresponding C-domain c unterparts, expressed in a 
mammalian cell culture system and purified to homogeneity. These mutant enzyme 
derivatives were subsequently tested with N-selective substrates and inhibitors. Information 
regarding their contributions can be used in the initial design of novel N-selective inhibitors. 
Assessment of the effects of these mutations in substrate processing involved substrates 
Z-FHL, HHL and Abz-SDK(Dnp)P. The S2 mutant Y369F showed markedly improved 
catalytic efficiency in the hydrolysis of HHL and molecular docking experiments confirmed 
that the presence of the phenolic hydroxyl group could obstruct the optimal positioning of 
HHL; thus lowering catalytic ability in the N-domain. The S2 mutants Y369F, R381E and 
YR/FE, but not T496V, all showed approximately 5-fold reduction in catalytic efficiencies of 
Abz-SDK(Dnp)P processing suggesting the cooperation of several other residues in allowing 
for selective hydrolysis. This was further corroborated with a C-domain S2´ mutant enzyme 
showing 10-fold improved catalysis compared to the C-domain control, suggesting that 
N-selectivity involves interplay between subsites for effective processing. Further 
sophisticated molecular modelling, as performed previously with another fluorogenic 
substrate (Bersanetti et al., 2004), could shed light on the possible interactions and dynamics 
involved in N-selectivity of substrate processing. Multiple mutations within a given subsite 
could allow for an investigation into the extent of cooperative binding between residues in 
allowing for effective catalysis to occur. Future work should also involve multiple mutations 
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in both subsites which could allow for an understanding of overall contribution across 
subsites to this process.   
A potentially high-throughput assay for AcSDKP kinetic determination was developed and 
showed similar N-domain catalytic constants to those published in the literature (Rousseau et 
al., 1995; Deddish et al., 1996). Surprisingly, the C-domain turnover rate was markedly 
higher than previous reports (approximately 40-fold) and thus N-selectivity was only 
approximately 2-fold for AcSDKP. This finding requires further investigation. The use of full 
length sACE molecules containing only a single functioning active site could assist in 
understanding the manner of how each domain regulates the other in AcSDKP processing. 
Other chimeras have been generated in our research group that involved a swap in domain 
orientation or sACE containing two C-domains (Woodman et al., 2005), which could be 
useful in further characterising the molecular nature of possible domain regulation in the 
hydrolysis of this important peptide. 
N-domain mutations were further assessed in their effect on binding of N-selective 
phosphinic inhibitor RXP407. This inhibitor showed prominent N-selectivity, displaying low 
nanomolar inhibition of the N-domain (Ki= 5.16 nM) and micromolar inhibition of the 
C-domain (Ki= 2.83 µM) consistent with the literature (Dive et al., 1999). Several mutations 
in the S2´ subsite (E262S, D354E, T358V and ST/VV) had no effect on inhibitor binding 
while S2´ subsite mutations S357V and E431D resulted in slight decreases in inhibitor 
affinity (S357V Ki= 20.5 nM, E431D Ki= 17.7 nM). Thus, S2´ mutations within plausible 
binding distance of the inhibitor had no considerable effect on inhibitor binding. The 
importance of the inhibitor P2´ group has been described elsewhere (Dive et al., 1999), thus it 
is likely that the production of an N-domain mutant containing all unique S2´ residues 
converted to corresponding C-domain counterparts would give an indication as to the full 
extent of S2´ subsite contribution in RXP407 binding. Also, the determination of the crystal 
structure of RXP407 in the C-domain could allow for improved understanding of the 
differences in P2´ group positioning between domains in this pocket. 
Analysis of mutations in the S2 subsite revealed the important role of this pocket in the 
N-selectivity of RXP407. Mutant T496V had no effect on inhibitor binding while mutations 
Y369F and R381E had minor decreases of inhibitor affinity (Y369F Ki= 18.0 nM, 
R381E Ki= 33.5 nM). However, conversion of both Tyr369 and Arg381 (mutant YR/FE) 
resulted in a 112-fold decrease in RXP407 binding affinity (Ki= 631 nM). This suggests that 
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both residues make contact with the inhibitor such that when one is removed the remaining 
residue can provide interactions to still allow for potent binding, in agreement with the 
recently solved crystal structure (Anthony et al., 2010). Complete loss of binding affinity to a 
level comparable to the C-domain (that is, in the micromolar range) was not achieved with 
any of the above mutations suggesting, as with the abovementioned substrate analyses, that 
interplay between subsites results in a total contribution towards N-selective binding. The 
next phase of this study should involve, as with substrate processing analyses, the use of 
mutants with conversions of multiple implicated residues across subsites and subsequent 
testing. This approach was employed in investigating the molecular basis of ACE C-domain 
selectivity and has already suggested important interplay between subsites for RXPA380 and 
RXP407 binding (Kroger et al., 2009). 
Previously described structural determinants for the N-selectivity of RXP407 were used in 
the design of novel N-selective inhibitors. C-terminally amidated captopril (capNH2) and 
keto-ACE molecules did not show improved N-selectivity and appeared to have reduced 
potency in inhibitor screens compared to controls (amidated keto-ACE failed to inhibit the 
N- and C-domains at 250 µM concentration whereas the parent molecule showed low 
micromolar range potency). The substitution of a P2 benzoyl moiety with an N-protecting 
group and Asp residue resulted in a 1000-fold change in N-selectivity. Structural perspectives 
in the form of molecular minimisation studies indicated the P2 Asp or t-Boc group had the 
ability to interact with S2 residues Tyr369 and Arg381. In agreement with mutational studies 
above, the S2/P2 interaction is considered very important for N-selective binding. Future work 
should involve the synthesis of a keto-ACE analogue containing both the P2 Asp/protecting 
group and an amidated C-terminus to investigate whether there could be cooperative effects 
between these two groups thereby synergising and improving N-selective binding of this 
series of compounds.   
Taking the analyses of both substrates and inhibitors together reveals the consistent role of 
the S2 subsite, particularly residues Tyr369 and Arg381, in contributing to differential domain 
kinetics. Tyr369 contributes to preventing improved HHL catalysis, both residues appear to 
assist in positioning Abz-SDK(Dnp)P for selective catalysis and both residues interact 
significantly with RXP407 and novel N-selective inhibitors. Thus, this study provides 
functional information involving active site mutation that further implicates the S2 subsite in 
providing important interactions for both substrate processing and inhibitor binding. 
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The current study also gives important direction regarding the design of N-selective 
inhibitors. Based on the above findings, it is recommended that inhibitor design focus on the 
optimisation of interactions with Tyr369 and Arg381. The formation of four hydrogen bonds 
of the P2 Asp with these residues is a large contributor to its selective binding of the 
N-domain ((Anthony et al., 2010) and this study). Thus, the addition of a P2 Asp to clinically 
relevant, non-domain selective inhibitors (for example, enalaprilat) could result in an increase 
in N-selectivity and produce an important lead in the development of N-selective drug 
candidates. Combinatorial chemistry resulted in the discovery of the P2 Asp playing an 
important role in N-selectivity (Dive et al., 1999); however, P2 functionalities should not be 
limited to naturally occurring amino acids but extended to the inclusion of other more novel 
P2 structures. Such low molecular weight compounds containing novel functionalities have 
been designed for other dipeptidyl peptidases and, in addition to good in vitro inhibition, 
displayed promising pharmacokinetic properties (Koo et al., 2007). 
Current ACE inhibitors contain structural similarity in that all inhibitors insert in an 
orientation on the ―primed side‖ of the zinc ion. Development of new classes of inhibitors 
involved an extension of these templates into the P1 and P2 groups (Redelinghuys et al., 
2005). While this extension could assist in potency and selectivity, it could possibly introduce 
issues of reduced drug-like characteristics (Walters et al., 1999). K-26, a potent 
phosphonotripeptide ACE inhibitor, was recently shown to bind exclusively with the S1 and 
S2 subsites of AnCE (Ntai and Bachmann, 2008; Akif et al., 2010b). Thus, this molecule 
provides a template in the development of a new class of low molecular weight ACE 
inhibitors. Such molecules could be synthetically modified to optimise interactions with 
Tyr369 and Arg381 and thus increase N-selectivity.  
In conclusion, this study has identified N-domain residues that contribute to the observed 
domain selectivity in substrate processing and inhibitor binding; and thus supplies useful 
information in the design of novel N-selective ACE inhibitors. The next generation of ACE 
inhibitors possessing improved N-selectivity could be useful in the treatment of conditions 
relating to tissue fibrosis without affecting blood pressure regulation. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
101 
 
Appendix 
 
A1. Molecular cloning 
A1.1 General information 
DH5α E. coli cells (genotype: F-, φ80lacZ∆M15, ∆(lacZYA-argF)U169, deoR, recA1, 
endA1, hsdR17(rk
-
, mk
+
), phoA, supE44, thi-1, gyrA96, relA1, λ-) (Invitrogen) were used for 
the transformation and propagation of plasmids. Bacterial culturing was carried out in luria 
broth medium (LB, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% NaCl) at 37°C and 200 
rpm shaking. Ampicillin (final concentration 50 µg/ml) was added to the medium after 
autoclaving in cases of antibiotic selection as described in the text. Agar plates (1% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 1% NaCl, 1.5% (w/v) bacteriological agar, 50 µg/ml 
ampicillin) were used in the plating of E. coli cells for single colony selection.  
A1.2 Preparation and transformation of competent cells 
Procedures regarding the preparation and transformation of DH5α cells were performed as 
described by (Sambrook et al., 1989). A single clone was picked and grown overnight in 5 ml 
LB medium. Five hundred microlitres of overnight culture was inoculated into 50 ml LB and 
grown under culturing condition until reaching an optical density at 595 nm (OD595) of 0.5-
0.6 units. Cells were harvested by centrifugation at 5000 rpm for 10 minutes at 4°C and the 
supernatant discarded. The cell pellet was resuspended in ice cold 10 ml 100 mM MgCl2 and 
incubated on ice for 30 minutes. Cells were centrifuged again as above and the supernatant 
discarded. The cell pellet was resuspended in 2 ml 85 mM CaCl2 (containing 15% glycerol), 
aliquoted in 100 µl aliquots into sterile reaction tubes and either used immediately or stored 
at -80°C for later use. 
For transformation, competent cells were thawed on ice and approximately 20 µl DNA 
solution added directly to the reaction tube. The DNA-cells mixture was incubated on ice for 
20 minutes, followed by heat shock of 5 minutes at 37°C and subsequent 1 minute incubation 
on ice. Four hundred and fifty microlitres of LB was added to the mixture and incubated at 
37°C for 60 minutes shaking. Transformants were plated out onto ampicillin agar plates and 
incubated overnight at 37°C. 
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A1.3 Crude small scale plasmid preparation (Sambrook et al., 1989) 
A selection of colonies displaying ampicillin resistance were inoculated into 5 ml LB 
containing antibiotic and grown overnight under bacterial culturing conditions. 
Approximately 1 ml of overnight culture was harvested through centrifugation on a bench-top 
centrifuge and the bacterial pellet re-suspended in 250 µl STET buffer (8% (w/v) sucrose, 
5% (w/v) triton X-100, 50 mM EDTA pH 8.0, 50 mM Tris-HCl pH8.0, 20 µg/ml 
ribonuclease A, 1 mg/ml lysozyme). The resuspension was vortexed and boiled for 1 minute 
followed by centrifugation for 8 minutes at room temperature. The viscous pellet was 
removed with a sterile toothpick and the remaining DNA-containing supernatant was 
precipitated by the addition of 250 µl isopropanol with thorough mixing. The mixture was 
centrifuged for 8 minutes at room temperature, the supernatant discarded and the DNA pellet 
air dried for approximately 10 minutes. The dried pellet was gently resuspended by the 
addition of 20 µl nuclease free dH2O and 1 to 3 µl used for restricti n enzyme digests. 
A1.4 Restriction endonuclease digests and agarose gel electrophoresis 
Restriction endonuclease digests were performed with prepared plasmid DNA. 
Approximately 1-10 units of restriction endonuclease activity was used in a buffer system 
recommended by the appropriate manufacturer of the enzyme. Endonuclease was incubated 
with the DNA and 1X buffer system in a final volume of 20 µl for 1 hour at 37°C (unless 
otherwise indicated in the text) and stopped by placement on ice and the addition of loading 
buffer (0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol). 
DNA fragments were fractionated and visualised by agarose gel electrophoresis. Prepared 
samples were loaded into a 1% agarose gel in TBE buffer (90 mM Tris-citrate pH 8.5, 90 
mM boric acid, 3.2 mM EDTA, 10 µg/ml ethidium bromide). Samples underwent 
electrophoresis at 75 V for 60-90 minutes and banding patterns visualised under UV 
emission. 
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A2. Heterologous protein expression 
A2.1 Mammalian cell culture medium components 
Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s nutrient mixture (Ham’s-F12) 
were purchased from Gibco
®
 (Invitrogen), foetal calf serum (FCS) was purchased from 
Sigma-Aldrich Co. and penicillin-streptomycin (Pen-Strep) purchased for Lonza Research 
Solutions. All medium was filter sterilised upon mixture of the components and sterility 
maintained at all times. 
Growth medium: 44% (v/v) DMEM, 44% (v/v) Ham’s-F12, 10% (v/v) FCS (heat 
inactivated- 56°C for 30 minutes), 20 mM Hepes pH 7.5. 
Harvesting medium: 48% (v/v) DMEM, 48% (v/v) Ham’s-F12, 2% (v/v) FCS 
(additional heat inactivation- 72°C for 30 minutes), 20 mM 
Hepes pH 7.5, 100 units Pen-Strep. 
Wash solution (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, KH2PO4           
pH 7.5. 
Glycerol shock solution: 15% (v/v) glycerol in PBS. 
A2.2 SDS polyacrylamide gel electrophoresis 
Acrylamide gels were cast and subsequently electrophoresed using the Mini-PROTEAN 
Tetra Electrophoresis System (BioRad Laboratories Inc.). All running gels were cast with 
10% acrylamide. Two and a half millilitres of 40% (w/v) acrylamide/bis-acrylamide (19:1) 
(Sigma-Aldrich Co.) was mixed with 3.3 ml running gel buffer (1.1 M Tris-HCl pH 8.8, 0.3% 
(w/v) SDS) and 4.1 ml dH2O (final volume 9.9 ml). Gel polymerisation was initiated with the 
addition of 0.1 ml 10% (w/v) AMPS (made fresh) and 7 µl TEMED and the polymerising 
solution covered with a layer of isopropanol to ensure a flat interface between stacking and 
running gels. Once the running gel was set, the isopropanol was removed. The stacking gel 
was prepared by the addition of 0.8 ml 40% (w/v) acrylamide/bis-acrylamide (19:1) to 3.3 ml 
stacking gel buffer (0.38 M Tris-HCl pH 6.8, 0.3% (w/v) SDS) and 5.6 ml dH2O (final 
volume 9.7 ml). Gel polymerisation was initiated with the addition of 0.3 ml 
10% (w/v) AMPS (made fresh) and 20 µl TEMED followed by the insertion of the supplied 
comb for the formation of gel loading wells and allowed to set. 
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The equipment for gel electrophoresis was assembled according to manufacturer’s guidelines. 
Five microlitres of loading buffer (62.5 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) 
glycerol, 5% (v/v) mercaptoethanol, 0.001% (w/v) bromophenol blue) was added to samples 
of 20 µl volumes and boiled for 5 minutes. The entire prepared sample was then loaded 
directly into the well of the above prepared acrylamide gels. Electrophoresis was performed 
in running buffer (25 mM Tris-HCl pH 8.3, 200 mM glycine, 1% (w/v) SDS) at a constant 
current of 50 mA and stopped when the dye front had eluted through the opposite end of the 
gel. 
After electrophoresis, the apparatus was dismantled and acrylamide gels were stained with 
Coomassie staining solution (0.25% (w/v) Coomassie brilliant blue, 50% (v/v) methanol, 
10% (v/v) acetic acid) for approximately 60 minutes. De-staining was performed by 
incubation of the gels with de-stain solution (25% (v/v) ethanol, 10% (v/v) acetic acid) for 2 
hours. 
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A3. Preparation of substrates for enzymatic assays 
A3.1 Internally quenched fluorogenic substrates (Abz-FRK(Dnp)P and Abz-SDK(Dnp)P) 
Substrates were obtained in solid form and were a kind gift from Dr A.K. Carmona 
(Universidade Federal de São Paulo, Brazil). The powder was dissolved in 100% DMSO to 
yield a 10 mM stock solution based on the extinction co-efficient ε365= 17300 M
-1
cm
-1
 
(Araujo et al., 2000). Substrates were subsequently diluted down in assay buffer to the 
required working stock concentration and used in enzymatic assays. 
A3.2 Z-Phe-His-Leu and Hippuryl-His-Leu  
HHL was purchased from Sigma-Aldrich Co. For a 5.7 mM working stock solution, 48.5 mg 
HHL was dissolved in 4.2 ml 0.025 M NaOH (with heating) followed by addition of 4.0 ml 
5X phosphate buffer (500 mM KHPO4/KH2PO4 pH 8.3), 2.0 ml 3 M NaCl, 9.8 ml dH2O and 
15 µl 10 mM ZnSO4. The working solution was stored at 4°C until use. 
Z-FHL was purchased from Bachem Ltd. For a 20 mM stock solution, 110 mg substrate was 
dissolved in 1 ml 0.28 M NaOH (with heating) followed by the dropwise addition of 9 ml 
dH2O. The stock solution was aliquoted out into reaction tubes at stored at -20°C. Working 
stock solutions were diluted down to the desired concentration with 5X phosphate buffer, 
NaCl, dH2O and ZnSO4 as above and stored at 4°C until use. 
A3.3 Ac-Ser-Asp-Lys-Pro 
AcSDKP was purchased from Sigma-Aldrich Co. and dissolved in sterile dH2O to yield a 
10 mM stock solution. A 2 mM working stock was obtained by dilution in HEPES buffer 
(50 mM HEPES, pH 7.5, 100 mM NaCl, 10 µM ZnSO4) and subsequently diluted to 
appropriate concentrations in the same buffer.  
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A4. Standard curves 
A4.1 Standard curves used for enzymatic assays 
Standard curves were empirically determined as described in Chapters 3 and 4. 
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Figure A1: Standard curve of His-Leu correlated with increasing fluorescence. 
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Figure A2: Standard curve of Abz-Gly correlated with increasing change in fluorescence 
(ΔFU). 
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Figure A3: Standard curve of Lys-Pro correlated with increasing change in fluorescence 
(ΔFU). 
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